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ABSTRACT 
 
The aim of this study was to utilize molecular biology knowledge to develop novel 
amplification-based technologies, which enable enrichment of challenging nucleic 
acid targets to a level sufficient for detection, including those with extremely long, 
GC-rich and/or repetitive sequences and low-abundance single nucleotide RNA 
variants in the excess of alternative variants. 
We have introduced multiple heat pulses in the extension step of a PCR cycling 
protocol to generate a novel amplification technology (HPE-PCR), which temporarily 
destabilize secondary structures, in order to enhance DNA polymerase extension over 
GC-rich sequences. These secondary structures have been thought to block the DNA 
polymerase during the extension step, leading to decreased amplification efficiency. 
Different GC rich target sequences in the human genome, extremely long Fragile X 
GGC repeats and Myotonic Dystrophy type 1 CTG repeats have been used as models 
to develop and validate this novel technology. The HPE-PCR cycling protocol 
enables amplification and detection of all expansions of GGC repeats in five Fragile 
X cell lines, as well as extremely GC-rich non-repetitive segments of the GNAQ and 
GP1BB genes. The longest Fragile X expansion contained 940 GGC repeats, 
corresponding to about 2.8 kilo bases of 100% GC content. It also improves the 
balance of amplification efficiencies between GC-rich target sequences of different 
length and thus enables amplification of all of the allelic expansions even in the 
presence of the unexpanded allele. 
In order to detect a low-abundance RNA variant, we devised a novel technology 
using a competitive Extendable Blocking Probe (ExBP) in the reverse transcription 
reaction for allele-specific priming with superior selectivity. In ExBP-reverse 
transcription, the mismatch priming site on the alternative variant is blocked by a 
perfectly matched ExBP. This initiates formation of a stable cDNA-RNA hybrid that 
completely blocks false cross-priming by the target specific primer. Following 
gradual temperature decrease in a hot-start fashion, a reverse-transcription primer 
whose sequence matches the specific target variant selectively primes only that 
variant. In experimental models, the ExBP-based reverse transcription assay allowed 
for detection of multiple mutation types on different genes in at least 1000-fold excess 
of wildtype RNA and detection was linear over a 4 log dynamic range. This technique 
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not only reveals the presence or absence of rare mutations with an exceptionally high 
selectivity, but also provides a convenient tool for accurate determination of RNA 
variants in different settings, such as quantification of allele-specific expression.  
In conclusion, we have established HPE-PCR and ExBP-RT techniques to enable 
enrichment of different nucleic acid templates that are currently challenging to  detect 
by PCR, such as long, GC rich and/or repetitive sequences as well as low-abundance 
point mutations in a vast excess of wildtype alleles. These techniques expand the 
capacities of current PCR technology; provide versatile and convenient research tools 
and open many new possibilities for its applications in molecular diagnostics. 
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INTRODUCTION 
 
Polymerase chain reaction (PCR) (Saiki et al. 1985, Saiki et al. 1988) has evolved 
into a popular and powerful approach for detection of nucleic acid targets with high 
sensitivity and specificity over the past thirty years. As the copy numbers of target 
sequence accumulate in an exponential manner during the course of PCR 
amplification, it is possible to quickly achieve a sufficient amount of DNA for 
detection in hours, or even minutes (Ahmad et al. 2012). As a consequence, PCR has 
become the basis of numerous applications and has initiated a revolution in molecular 
diagnostics, enabling a number of applications that were impossible in the pre-PCR 
era. In spite of its versatility and speed, conventional PCR sometimes failes to enrich 
particular DNA sequence targets to a level sufficient for detection, consequently, 
many modifications and developments have been necessary in order to expand the 
applicability of PCR. 
DNA targets with a great length, high GC content and/or repetitive sequence represent 
a class of nucleic acid templates that are refractory to PCR-based detection due to the 
formation of thermo-stable secondary structures. These secondary structures either 
prevent primer annealing or block the DNA polymerase during the extension step of 
PCR amplification. This results in attenuated amplification and at worst, reduces 
amplification efficiency in such a way that the final product may be below the 
detection limit even at the plateau phase of PCR. Although numerous developments, 
both in PCR reagents and PCR cycling protocols, have been made to date, there are 
still situations where certain difficult templates cannot be amplified by PCR.  
We hypothesized that stable secondary structures in long GC-rich and/or repetitive 
sequences could be temporally destabilized, by rapid temperature fluctuating during 
the extension step in order to improve DNA polymerase extension. This would allow 
complete extension of a greater proportion of the annealed primers, with a subsequent 
increase in both amplification efficiency and specificity and promote successful 
amplification of such difficult sequences. In order to improve amplification efficiency 
over long GC-rich and/or repetitive sequences, we developed a novel PCR cycling 
technique: Heat Pulse Extension PCR (HPE-PCR), which utilizes subcycling with 
multiple heat pulses during each extension step. We applied the HPE-PCR technology 
for amplification and enrichment to enable detection and sizing analysis of extremely 
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large and GC-rich repeat expansions in Fragile X syndrome (GGC repeats) and 
Myotonic Dystrophy type 1 (CTG repeats).  
Another class of nucleic acid templates that are challenging to be detected using 
PCR are low-abundance single nucleotide RNA variants, particularly when they occur 
in a vast excess of alternative variants. Allele-specific PCR (AS-PCR) and 
modifications thereof have been popular in detection of single-nucleotide variants 
(Newton et al. 1989, Wu et al. 1989). These techniques usually have a modest 
selectivity due to considerable cross amplification and cannot be universally 
generalized for mutation detection assays (Ayyadevara et al. 2000). An alternative 
approach has been to utilize allele-specific priming during reverse transcription in 
order to transform highly similar RNA variants into distinguishable allele-specific 
cDNA products prior to PCR amplification. Reverse transcriptases are, however, 
capable of initiating primer extension from a mismatched primer with a relatively 
high efficiency (Mendelman et al. 1990, Creighton et al. 1992) and this type of assays 
has been hampered by a high level of mismatch priming. As a consequence, it has not 
been possible to achieve appropriate selectivity for allele-specific priming during 
reverse transcription using this stragtegy.  
In order to enable sensitive detection and accurate quantification of low-abundance 
RNA variants, we introduced Extendable competitive Blocking Probes in Reverse 
Transcription (ExBP-RT) to devise a novel and universal strategy for this specific 
purpose. The ExBP-RT technique utilizes a hot-start reverse transcription protocol in 
which the more abundant wildtype RNA template is primed by an extendable 
wildtype-specific competitive blocking probe and initiates cDNA synthesis to form a 
thermostable cDNA-RNA hybrid. This double stranded hybrid nucleic acid efficiently 
blocks the mismatch priming. The mutated target RNA template is selectively primed 
during reverse transcription using a mutation-specific primer, containing an 
oligonucleotide tail at its 5’ end that allows selective amplification of the mutation-
specific product in the following amplification step. The ExBP-RT assay provides a 
simple, universally applicable strategy for ultrasensitive detection of expressed 
mutations, which might reflect the functional consequences brought upon the cells or 
tissues more faithfully than a DNA-based mutation detection assays (Yan et al. 2002). 
As an example of utility, this novel technology was successfully utilized to detect the 
most common KRAS mutations in formalin-fixed paraffin embedded tissues from 
colorectal cancer patients. 
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REVIEW OF THE LITERATURE 
 
1. POLYMERASE CHAIN REACTIONS AND AMPLIFICATION 
EFFICIENCIES 
1.1.	  Polymerase	  chain	  reaction	  (PCR)	  
The polymerase chain reaction (PCR) is a biochemical technology for in-vitro 
exponential amplification of a particular DNA sequence template (Saiki et al. 1985, 
Mullis et al. 1986). Since the discovery of PCR almost three decades ago, this 
amplification technology has been actively developed and widely utilized for diverse 
applications in molecular biology. In principle, PCR employs multiple thermal cycles, 
each of which consists of a denaturation step (heating) for DNA melting; a 
hybridization or annealing step (cooling) for primers binding to complementary strand 
of target region; and an extension step for extension of annealed primer or DNA 
replication, which is catalyzed by a DNA polymerase (Figure 1A). In PCR, each 
copy of the DNA target sequence formed in a cycle will serve as template to produce 
two copies of the same sequence in the following cycle, therefore, the DNA template 
is, in theory, amplified exponentially with the power of two, and billion copies of 
product can be quickly generated from one or few copies of template after about 30 
PCR cycles (Figure 1B). 
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Figure 1: Schematic of polymerase chain reaction (PCR) in each cycle (A): a 
denaturation step at high temperature for DNA melting, an annealing step at a low 
temperature for primers binding to complementary strand of target region, and an 
extension step at about 72°C for extension of annealed primer, which is catalyzed by 
a DNA polymerase; and accumulation of PCR product after 30 cycles (B): DNA 
target copy number increase exponentially after each cycle, and billion copies of 
product can be quickly generated after about 30 PCR cycles. 
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1.2.	  Amplification	  efficiencies	  and	  PCR	  bias	  
The PCR amplification efficiencies are, in reality, usually suboptimal and are 
negatively affected by various factors, including the nature of target sequences (e.g. 
length, GC content and the repetitiveness of amplicons), primer design, quality of 
oligonucleotide synthesis as well as other PCR conditions, such as temperatures and 
time for different steps within each thermal cycle, buffer properties, salt 
concentrations and characteristics of DNA polymerase enzymes. As a consequence, 
stringent optimization of PCR protocols is normally required for many DNA or 
cDNA templates, in order to realize the optimal PCR efficiency.  
Thermostable secondary structures and template re-annealing problem resulting 
from such difficult sequences (Figure 2), are considered to be the major obstacles, 
which block the DNA polymerase from completing the extension of annealed primers 
during PCR (Chou 1992, Usdin et al. 1995, McDowell et al. 1998). In this type of 
sequences, template re-annealing (Ouldridge et al. 2013) or decreased hybridization 
kinetics of primer annealing due to secondary structures (Gao et al. 2006) might also 
reduce the reaction efficiency by preventing primer annealing. Secondary structures 
may arise from duplexes between the opposite strands of GC-rich sequences, as a 
result of either incomplete denaturation or re-annealing, when the reaction 
temperature decreases towards the annealing step (McDowell et al. 1998). In addition, 
strong secondary structures can form as a result of intra-molecular folding of the 
separate DNA strands (Chou 1992, Chen et al. 1995, Usdin et al. 1995, Darlow et al. 
1998). Such secondary structures are thought to block DNA polymerase activity 
during the extension step, resulting in incomplete extension products, low extension 
efficiency and ultimately, inefficient amplification of the specific products. As a 
result, amplification of non-specific products occurs more commonly in PCR 
amplification of GC-rich sequences despite attempts at optimizing cycling protocols 
(Mamedov et al. 2008). 
If more than one template of different lengths and GC-contents is co-amplified in 
the same PCR assay (multi-template PCR), these templates might be amplified with 
varying efficiencies, which is known as “PCR bias”. As the GC-rich, long and/or 
repetitive templates are amplified with reduced efficiency; they might not be 
sufficiently enriched in the final amplification products. Consequently, detected 
signals derived from amplification of such difficult sequences might be greatly 
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attenuated and often below the detection limit when more easily amplified templates 
are present in the same reaction. This hampers the performance of several multi-
template PCR applications, such as amplification of nucleic acid libraries and 
amplification of GC-rich repeat expansions underlying numerous inherited diseases in 
the presence of unexpanded alleles (Bowater et al. 2001, Mirkin 2006, Mirkin 2007). 
If these repeat expansions are relatively short, PCR amplification over the repeats is 
possible in most cases, and fragment analysis on automated DNA sequencers is a 
routine procedure in diagnostic laboratories. However, the causative repeat 
expansions in many diseases are very long and/or of extremely high CG contents, 
which make these expansions refractory to PCR amplification, especially when an 
additional copy of the unexpanded allele is present. If PCR conditions are suboptimal, 
the shorter wildtype allele monopolizes the amplification reaction, resulting in lack of 
amplification of the expanded allele. 
 
Figure 2: Suppression of PCR by secondary structures resulted from GC-rich, 
repetitive templates. Primer annealing is prevented by a hairpin (A), incomplete 
denaturation or re-annealing (D); primer extension is suppressed by a hairpin (B), a 
quadruplex (C), incomplete denaturation or re-annealing (D), or a stable secondary 
structure resulted from a (GGC) repeat in Fragile X syndrome (E). (DNA target strand 
in “blue”, primer or complementary strand in “red”; and DNA polymerase in 
“turquoise”) 
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1.3.	  PCR	  amplification	  of	  GGC-­‐repeat	  expansions	  in	  Fragile	  X	  syndrome	  
Fragile X syndrome is one of the most common forms of inherited intellectual 
disorders, and it was the first human disease linked to triplet repeat expansions. The 
expansion of GGC repeats in the 5’-untranslated region of the X chromosomal Fragile 
mental retardation 1 (FMR1) gene is the cause of this syndrome (Verkerk et al. 1991). 
Typical Fragile X syndrome is caused by so called full-mutation expansions 
containing more than 200 repeats (Maddalena et al. 2001), which are abnormally 
methylated (Oberle et al. 1991). Pre-mutation expansions containing from 55 to 200 
repeats relate to other syndromes, such as fragile X–associated tremor/ataxia 
(Hagerman et al. 2001) or fragile X–associated primary ovarian insufficiency 
(Allingham-Hawkins et al. 1999, Murray et al. 2000). These pre-mutations might 
develop into full-mutation expansions in the next generations (Nolin et al. 2003, 
Fernandez-Carvajal et al. 2009). 
It seemed that PCR technique would provide a powerful solution, which is high-
throughput, fast and simple, for sizing analysis of these repeat expansions. In reality, 
however, it is difficult to amplify over these sequences using conventional PCR. The 
extremely high GC content (100%) and the intra-molecular interaction of these 
repetitive sequences lead to the formation of very stable hairpin structures (Chen et al. 
1995, Darlow et al. 1998). In addition, the presence of unexpanded alleles in female 
samples makes it even more challenging to amplify the full-mutation expansions. It is 
obvious that the shorter wildtype alleles will be extended with a higher efficiency 
during PCR. Thus the reaction will be dominated by the amplification product of the 
shorter wild-type allele and the full-mutation expansion will not be enriched to a level 
sufficient for detection (Haddad et al. 1996). Up till now, no optimal PCR program 
using standard reagents is capable of amplifying full-mutations longer than 330 
repeats in male samples or 160 repeats in carrier female samples, despite the 
introduction of advanced PCR reagents (Baskaran et al. 1996, Brown et al. 1996, 
Haddad et al. 1996, Hamdan et al. 1997, Houdayer et al. 1999, Hecimovic et al. 2001, 
O'Connell et al. 2002, Saluto et al. 2005).  
 
1.4.	  PCR	  amplification	  of	  CTG-­‐repeat	  expansions	  in	  Myotonic	  Dystrophy	  type	  
1	  (DM1)	  
Myotonic dystrophy type 1 (DM1) is the most common inherited neuromuscular 
disease in adults, with an incidence of 1 in 8000 individuals globally. It is a multi-
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systemic disorder characterized primarily by myotonia and progressive muscle 
weakness. DM1 is an autosomal dominant disease, which is caused by increasing 
number of CTG repeats in the 3’ untranslated region of the Dystrophia Myotonica 
Protein Kinase (DMPK) gene (Mahadevan et al. 1992, Imbert et al. 1993). Unaffected 
individuals carry two alleles of 5 to 34 CTG-repeat units, while affected patients carry 
an expanded mutant allele of more than 50 CTG-repeats and sometimes over 2000 
repeat units. The severity of the disease in successive generations and the age of 
disease onset positively correlate with an increase in the number of triplet nucleotide 
repeats (Harley et al. 1992, Hunter et al. 1992, Tsilfidis et al. 1992). As a 
consequence, detection and sizing analysis of CTG-repeat expansions in DM1 is 
clinically important. 
Currently, molecular diagnostics of CTG expansions in DM1 primarily relies on 
Southern blot analysis. This technique is, however, laborious, time-consuming, and 
not suitable for high-throughput screenings. Moreover, it requires large amounts of 
good-quality genomic DNA as input (Radvansky et al. 2010). Although PCR-based 
methods represent a promising strategy, which is apparently much more convenient in 
procedure in comparison to Southern blotting, the amplification of large CTG-repeat 
expansions by PCR is challenging due to great lengths of expanded alleles (Cheng et 
al. 1996) and stable secondary structures resulted from long GC-rich and repetitive 
sequences (Pearson et al. 1996). Preferential amplification of the unexpanded 
wildtype allele causes an even lower amplification efficiency of the expanded alleles 
and the amplification product originating from the shorter wildtype allele will 
eventually dominate the reaction. As a result, a detection limit of about 80 – 100 CTG 
repeats is common in conventional PCR methods used for molecular diagnosis of 
DM1 (Radvansky et al. 2010). With various modifications of PCR reagents and 
enzymes, such as rTth DNA polymerase, long-template additives, GC-enhancer, Taq-
stabilizer and partial substitution of 7-deaza-dGTP, expansions of about 800 CTG 
repeats have been detected after direct visualization of PCR products on agarose gels 
(Cheng et al. 1996, Skrzypczak-Zielinska et al. 2009). In spite of these improvements, 
techniques based on conventional PCR cycling protocols still fail to amplify many 
full-mutation expansions. 
 
	  18	  
2. CURRENT SOLUTIONS FOR ENRICHMENT OF LONG, GC-
RICH AND/OR REPETITIVE SEQUENCES 
In order to enable or improve specific amplification of difficult target sequences 
(long, GC-rich and/or repetitive sequences), there have been numerous developments 
and technical modifications made to the conventional PCR method. These 
modifications of PCR method can be categorized into two groups, reagent 
development and optimization of cycling protocols. 
 
2.1.	  Advanced	  reagents	  for	  amplification	  of	  difficult	  sequences	  	  
! Blends of DNA polymerases: Because the thermostable Taq DNA 
polymerase, commonly used in PCR, lacks 3’-5’ exonuclease activity, it has 
low fidelity and occasionally incorporates a mismatched base pair into the 
growing strand of primer extension product. This site of mismatched base pair, 
in turn, will lower extension efficiency, and this has been postulated as the 
cause for length limitation in PCR amplification. A high-fidelity DNA 
polymerase, which less likely incorporates mismatched base pair, would seem 
to be an attractive alternative to overcome the challenges associated with 
length limitation in PCR. However, this class of high fidelity DNA 
polymerases will significantly degrade primers using its inherent 3’-5’ 
exonuclease activity, eventually leading to reduced amplification efficiencies, 
particularly when longer incubation times are preferred for amplification of 
long PCR products. It was then discovered that long PCR products of up to 35 
kb in length could be successfully amplified using a DNA polymerase blend, 
which includes a high level of Taq DNA polymerase without 3’-5’ 
exonuclease activity and a very low concentration of another high-fidelity 
DNA polymerase with 3’-5’ exonuclease activity, such as Pfu, Vent DNA 
polymerase (Barnes 1994). It is indicated from this study that a low level of 
high-fidelity DNA polymerase is sufficient for removal of mismatches 
incorporated, and optimal for the Taq DNA polymerase amplification to 
continue efficiently. This blend of DNA polymerases, which is commercially 
available from different resources, has now become a routine for amplification 
of long and GC-rich target sequences. 
! PCR additives: Various detergents, organic solvents and additives have been 
found to be helpful for PCR amplification of difficult sequences, such as 
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betaine, dimethyl sulfoxide (DMSO), formamide/other small amides, glycerol, 
polyethylene glycol, trehalose, single stranded DNA-binding protein (SSB) 
and bovine serum albumin (Bachmann et al. 1990, Pomp et al. 1991, Sun et al. 
1993, Barnes 1994, Seto et al. 1995, Baskaran et al. 1996, Henke et al. 1997, 
Voss et al. 1998, Chakrabarti et al. 2001, Spiess et al. 2004, Farell et al. 2012). 
Different combination of these additives, co-solvents and/or detergents in the 
same PCR reaction have also been reported to be powerful in certain 
challenging PCR applications (Musso et al. 2006, Sahdev et al. 2007, 
Filipovic-Sadic et al. 2010). These additives have been shown to disrupt base 
pairing in the DNA double helix (Lee et al. 1981), or equalize the contribution 
of GC and AT base pairing to the stability of the DNA duplex, also known as 
“iso-stabilizing effect” (Rees et al. 1993). However, when concurrently used 
in the same reaction, these additives might behave in a relatively unpredictable 
manner. A number of investigators have proposed that these additives exert 
their beneficial effect in PCR amplification of difficult templates by 
destabilizing the DNA double helix (Cheng et al. 1994, Varadaraj et al. 1994, 
Spiess et al. 2004), thus assisting complete separation of double-stranded 
template during the denaturation step and preventing the formation of 
secondary structures during annealing and extension steps. This would result 
in more efficient and specific primer annealing, more complete primer 
extension and eventually improved efficiency of PCR amplification. In 
addition to the destabilizing effect on DNA double helix, some additives, such 
as glycerol and trehalose, have been found to have a thermal stabilization 
effect on DNA polymerase or even accelerate the enzyme activity (Spiess et 
al. 2004), which might also contribute to the improved PCR amplification 
efficiency. 
! Modified nucleotides: The 7-deaza dGTP analog, which is structurally 
similar to dGTP, is the most widely used modified dNTPs for PCR 
amplification of GC-rich targets. In contrast to dGTP, 7-deazadGTP analog 
lacks nitrogen at the 7 position of the purine ring (Figure 3B). Consequently, 
GC base pairs involving 7-deaza dGTP are significantly destabilized and the 
formation of the Hoogsteen bond known for natural dGTP is blocked, 
therefore the probability of forming strong secondary structures, such as stable 
hairpin or G quadruplexes is reduced (Frey et al. 2008). The combination of 7-
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deaza dGTP analog and natural dGTP at different ratios has been consistently 
reported to be valuable for PCR amplification of difficult templates 
(McConlogue et al. 1988, Fernandez-Rachubinski et al. 1990, Dierick et al. 
1993, Musso et al. 2006, Frey et al. 2008, Wei et al. 2010); Similar to 7-deaza 
dGTP structure, the dITP represents another economical option of nucleotide 
modifications, which also helps to destabilize GC base pairing (Figure 3C) 
and it has proved useful for PCR amplification of GC-rich templates (Dierick 
et al. 1993). Apart from modification of dNTP, the approach of chemically 
modifying the template DNA using sodium bisulfite for deamination of 
cytosine (C) into thymine (T) has been established to successfully amplify 
unusually high-GC DNA sequences, that are refractory to conventional PCR 
(Horiuchi et al. 2005). 
 
Figure 3: Base pairing of conventional nucleotides G/C (A) and those of modified 
nucleotides, which are useful for amplification of long, GC-rich and/or repetitive 
sequences: 7-deaza-G lacking N at the 7 position – dark circle (B); and Inosine 
forming only 2 hydrogen bonds with Cytosine (C) 
2.2.	  Optimal	  PCR	  cycling	  protocols	  for	  amplification	  of	  difficult	  sequences	  	  
In addition to extensive development of advanced reagents for PCR amplification 
of difficult templates, different optimal PCR cycling protocols have also been 
introduced to substantially support amplification of difficult sequences. 
! “Two-Step hot PCR” technique makes use of high-melting PCR primers, 
which are able to hybridize to target sequences at a considerably high 
temperature. Consequently, the annealing and extension steps are combined 
and performed at a single temperature of about 70°C – 80°C (Schuchard et al. 
1993). This technique will maintain the reaction temperatures sufficiently 
high, even when the reaction is cooled down to the annealing step. As a 
consequence, it will prevent or minimize the formation of potential secondary 
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structures, therefore, improving the efficiency of amplification of GC-rich 
DNA sequences. 
! “Touchdown PCR” or “Stepdown PCR” techniques employ different 
annealing temperatures, which are programmed to decrease during the course 
of PCR (Don et al. 1991, Hecker et al. 1996). In these PCR protocols, 
annealing temperatures of the first thermal cycles is programmed to be higher 
than the expected primer annealing temperature, and these temperatures are 
gradually decreased to a sufficiently low temperature in the following PCR 
cycles. These approaches increase PCR product specificity because non-
specific priming is less likely to occur at the beginning of the PCR program 
with high annealing temperatures. On the other hands, lower annealing 
temperatures in the following cycles of PCR will ensure high amplification 
efficiencies, thus resulting in sufficient yield of specific PCR product. 
! The “Slow down PCR” technique employs prolonged cycles and small 
ramping rates, in addition to the usage of different annealing temperatures 
during the course of PCR, similar to “Touchdown PCR” (Bachmann et al. 
2003, Frey et al. 2008). The exceptionally high number of PCR cycles (60 
cycles) and the slow cooling rate to annealing step of 1.5°/second in the “Slow 
down PCR” protocol allows for effective exact primer annealing. Furthermore, 
the primer design with short amplicon lengths and the usage of 7-deaza are 
critical for the success of this technique. 
! “Hotstart and Touchdown PCR” techniques combine “Touchdown PCR” with 
hotstart PCR protocols (Hube et al. 2005). Since a PCR hotstart protocol 
reduces spurious priming and non-specific amplification, which are commonly 
observed in PCR of GC-rich templates, it would favour amplification of 
specific PCR products and improve even further PCR amplification efficiency. 
Based on the same principle as “Hotstart and Touchdown PCR”, Wei M and 
co-worker recently reported the “SAFE PCR” method, which exploits a 
manual hotstart technique and an extremely stringent denaturation (98°C x 5 
minutes for initial denaturation and 98°C x 30s for denaturation in each PCR 
cycle) for complete separation of GC-rich duplex templates (Wei et al. 2010). 
Although this method has been reported to be powerful, it requires multiple 
additions of DNA polymerase during the course of PCR, the procedure of 
which is laborious and inconvenient. 
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! In summary, almost all existing strategies to optimize PCR cycling protocols 
focus on fine-tuning the annealing step, which consequently disfavors non-
specific PCR amplification. This increases amplification efficiencies for 
specific PCR products, accordingly facilitating amplification of difficult 
sequences. In spite of these improvements, amplification of long, extremely 
GC-rich and/or repetitive fragments still remains challenging and in some 
cases impossible. 
3. COLORECTAL CANCERS AND SOMATIC MUTATIONS 
3.1.	  Colorectal	  cancer	  
Colorectal cancer (CRC) remains an important public health problem, particularly 
in many Western countries (Parkin et al. 2005, Ferlay et al. 2007, Center et al. 2009, 
Jemal et al. 2009). Around 20-25% of patients with CRC present with metastasis at 
initial diagnosis, and an additional 25-35% of patients will develop metastases during 
the course of their diseases (Van Cutsem et al. 2006, Jemal et al. 2009). While early-
stage CRC is frequently curable with surgery and is associated with a 5-year survival 
rate of around 90%, the prognosis for patients with metastatic CRC (mCRC) remain 
poor, with a 5-year survival rate of 10-20% (Jemal et al. 2009, Kopetz et al. 2009). 
For patients with mCRC who have potentially resectable disease, preoperative 
conversion chemotherapy is being increasingly used with the aim of downsizing 
initially unresectable CRC to allow tumor excision (Pozzo et al. 2008, Van den Eynde 
et al. 2009). According to National Comprehensive Cancer Network, patients with 
non-resectable disease generally receive palliative chemotherapy aimed at alleviating 
and controlling symptoms, and improving quality of life and survival (NCCN 2009). 
The development of targeted biological agents has resulted in the approval of 
several monoclonal antibodies (mAbs) for use in patients with mCRC within the past 
few years, including cetuximab (Erbitux, Merck KGaA) and panitumumab (Vectibix, 
Amgen) (Patel 2008, Puthillath et al. 2009). These two agents bind to the epidermal 
growth factor receptor (EGFR), blocking the EGFR signaling cascade and thus 
inhibiting tumor growth (Mendelsohn et al. 2003, Hoda et al. 2008). In contrast to 
cetuximab, panitumumab is a fully human mAb that does not contain murine portions 
of mouse antibodies that are potential sources of immunogenicity. Anti-EGFR mAb 
monotherapy is an effective treatment option for heavily pretreated patient with 
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mCRC who are unable to receive further chemotherapy treatment (Bouche et al. 
2010). 
Understanding the reasons for treatment failure and developing an ability to predict 
those who would benefit the most (and least) remain important aims in the 
management of CRC (Walther et al. 2009). One of the most important discoveries for 
the clinical management of CRC is the association of mutations in KRAS and the 
efficacy of monoclonal antibodies targeting EGFR, such as panitumumab and 
cetuximab. In 2006, Lievre and collaborators hypothesized that mutations in the 
downstream effectors of EGFR signaling, such as KRAS, could explain resistance to 
anti-EGFR therapy (Lievre et al. 2006). These authors reported a retrospective study 
with 30 patients in which the presence of KRAS mutations in codon 12 or 13 was 
associated with a lack of response to the EGFR inhibitor cetuximab (Lievre et al. 
2006). 
3.2.	  KRAS	  mutations	  in	  cancers	  
The KRAS gene encodes for one of the proteins in the EGFR signaling pathway 
that is critical in the development and progression of cancer. Mutation of KRAS is an 
early event in the adenoma-carcinoma sequence, although mutations are demonstrable 
in only approximately one-third of CRC, with a large majority located in codon 12 
(Andreyev et al. 1998). Population based studies have shown that approximately 30% 
to 40% of CRCs harbor mutations in KRAS that yield a constitutively active protein 
(Samowitz et al. 2000, Brink et al. 2003, Ogino et al. 2007). These mutations 
typically occur in codons 12 and 13 (exon 2) or in codon 61 (exon 3) of the KRAS 
gene (Bos 1989). They compromise the hydrolysis of ras-bound GTP to GDP, 
resulting in constitutive activation of the ras pathway (Figure 4). Data have shown 
that tumors with KRAS mutations do not respond to EGFR inhibition (Karapetis et al. 
2008). These findings strongly suggest that testing of KRAS mutation is useful to 
predict the response to mAb targeting EGFR and this has become mandatory in many 
countries. 
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Figure 4: KRAS activating mutations and KRAS signalling pathway. Activating 
KRAS mutations compromise the hydrolysis of ras-bound GTP to GDP, leading to 
constitutive activation of the ras pathway and eventually up-regulation of 
proliferation, anti-apoptosis, angiogenesis, survival and metastasis. 
Methodologies used to test for KRAS mutation were reviewed more than a decade 
ago (Nollau et al. 1997). It is still unclear which of the currently available method of 
testing can be most effectively applied to clinical material while meeting the 
turnaround time requirement of current targeted treatment protocols. The current gold 
standard for KRAS testing remains direct sequencing of PCR amplification products 
(Nollau et al. 1997). This method detects all mutations in amplified DNA sequences, 
but mutant copies must have a concentration that is at least 20% - 50% of any 
accompanying wildtype sequences, a sensitivity that may not be optimal for clinical 
testing (Frayling 2002). Two recently described methods, high resolution melting 
analysis (Krypuy et al. 2006, Do et al. 2008, Simi et al. 2008) and amplification 
refractory mutation system (ARMS) (Newton et al. 1989, Fox et al. 1998, Clayton et 
al. 2000), which incorporates a unique bifunctional fluorescent primer/probe molecule 
(Scorpion) (Whitcombe et al. 1999, Thelwell et al. 2000), have a high sensitivity and 
specificity for detection of KRAS mutations with low turnaround time, and  could be 
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applied in a clinical setting. All these methods are designed to detect KRAS mutations 
at the DNA level and they are mainly qualitative analysis.  
3.3.	  Significance	  of	  low-­‐abundance	  point	  mutations	  
Single nucleotide polymorphisms (SNPs) and point mutations are the most 
common type of genetic polymorphism (Altshuler et al. 2005), which have been 
widely investigated as important markers in numerous applications. In cancer genetics 
and diagnostic applications, there is frequently a need for detection of a mutation in a 
sample comprising both wildtype and mutant sequences. It has been reported that tumor 
biopsies are generally heterogeneous and contain a mixture of many cell types, including 
stromal cells and tumor cells, which encompass diverse genetic and mutation profiles. 
Therefore, even a ‘‘pure’’ cancer biopsy is not genetically homogeneous (Rubin 2002). In 
many cases, wild-type DNA vastly exceeds mutant DNA, making it difficult to detect 
low-abundance mutation present at extremely low concentrations (Nollau et al. 1997). 
On the other hand, mutations in even a minimal proportion of the tumour cells or 
viruses can cause complete resistance to therapies (Flys et al. 2005, Lievre et al. 
2006). As a consequence, it is often beneficial or necessary to use an enrichment 
method to increase the concentration of the low-abundance mutation to a level 
feasible for accurate and reliable analysis. Enrichment of low-abundance mutations is 
particularly valuable for noninvasive diagnosis and early detection of mutations in bodily 
fluids (plasma, serum, urine) and human feces (Zhang et al. 2011, Thierry et al. 2014), 
which normally contain only trace amounts of mutations in a successive background of 
wildtype alternative (Parsons et al. 1997). Enrichment of low-abundance mutations is also 
helpful for assessment of residual disease after treatment (Milbury et al. 2009), studying 
mitochondrial disease (Sternberg et al. 1998), and for population screening of 
mutation/polymorphism in a mixed DNA sample, which is pooled from DNA samples of 
many individuals (Barcellos et al. 1997). 
4. METHODS FOR ENRICHMENT OF LOW-ABUNDANCE POINT 
MUTATIONS 
Many mutation detection methods have been described to date and most known 
methods begin with amplification of the target genome DNA sequence through the 
polymerase chain reaction (PCR), which is followed by an allele discrimination 
reaction and then detection/identification of allele-specific products (Chen et al. 
2003). The allele discrimination reaction, which is the core of a mutation detection 
technology, produces allele-specific products using a DNA polymerase, a DNA ligase 
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or a DNA hybridization reaction. The selectivity and accuracy of a method is largely 
dependent on the mechanism used in the allele discrimination reaction and how this 
mechanism is devised in a particular assay. Each technology exhibits advantages and 
disadvantages, and no methodology has been superior to all others in every 
application. 
4.1.	  Mutation	  detection	  based	  on	  DNA	  polymerase	  specificity	  
4.1.1.	  Allele-­specific	  PCR	  (AS-­PCR)	  	  
 This technology has been developed and reported by a number of groups under 
different names, such as “amplification refractory mutation system” (ARMS) 
(Newton et al. 1989, Newton et al. 1991, Tan et al. 1994, Chan Yoke et al. 2001), 
“PCR amplification of specific alleles” (PASA) (Sommer et al. 1989), “allele-specific 
amplification” ASA (Okayama et al. 1989), or “allele-specific PCR” (AS-PCR) (Wu 
et al. 1989, Rowley et al. 2010, Toni et al. 2010). In principle, allele-specific PCR 
exploits a discriminating primer, which is fully complementary to one allele (e.g. 
mutant sequence), but forms a mismatch with the other allele (e.g. wildtype 
sequence). The mismatched base is usually located at or near the 3’ end of the 
discriminating primer to prevent primer extension on that template by a DNA 
polymerase. However, the mismatched base may sometimes be located in the centre 
of the primer sequence, so that it will prevent primer annealing to the unexpected 
templates (Gibbs et al. 1989). It is assumed that primer annealing and extension 
occurs only when the primer is fully complementary to the target template, therefore, 
only one template allele that matches primer sequence is amplified. 
 In practice, mismatched extension at the 3’ ends of the primers may occur with 
varying degrees in AS-PCR, depending on assay conditions, local sequence context 
and especially the mismatch type. In particular, the PCR product yields decrease by 
100 fold for A:G, G:A, or C:C mismatches and by 20-fold for A:A mismatches, 
whereas all other mismatch types are efficiently amplified and those mismatches 
involving T have minimal effect on PCR product yield (Kwok et al. 1990). As a 
consequence, extensive optimization of primer design and reaction conditions, such as 
concentrations of magnesium, primers, deoxyribonucleotides, target DNA, DNA 
polymerase and addition of PCR additives, is often required to reduce primer 
extension from mismatched base and, therefore, improving the specificity of AS-PCR 
assays (Sommer et al. 1992, Bottema et al. 1993). In addition to adjusting the reaction 
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conditions, several proprietary reagents have been reported to improve AS-PCR 
specificity, such as oligonucleotides containing modified nucleotides (Latorra et al. 
2003, Ugozzoli et al. 2004), or the introduction of different non-extendable blocking 
probes into the reaction (Seyama et al. 1992, Orou et al. 1995). 
 Originally, mutation detection was performed using two parallel AS-PCR assays, 
one to amplify the mutant allele and the other to amplify the wildtype. 
 Subsequently, multiplex AS-PCR assays were developed, in order to allow for 
simultaneous detection of different alleles in a single PCR assay. Allele-specific 
products formed in such an assay can be discriminated using different fluorochromes 
attached to specific primers (Chehab et al. 1989, Kropp et al. 1991). Alternatively, the 
specific primers used may be of different lengths, which finally result in different 
sizes of amplification products (Li et al. 1990, Dutton et al. 1991), that can then be 
discriminated conveniently by agarose gel electrophoresis. More recent developments 
combining allele-specific PCR with real-time quantitative PCR techniques allows 
convenient monitoring of template amplification in a single tube, and makes the 
technique compatible with high-throughput analysis of multiple samples (Clayton et 
al. 2000, Morlan et al. 2009). 
4.1.2.	   Single	   nucleotide	   primer	   extension,	   also	   known	   as	  
“minisequencing”	  
In this group of methods, both mutant and wildtype sequences are co-amplified by 
PCR in the first step, and the amplification products will then be used as templates for 
the allele discrimination reaction, which is, in this case, is achieved by addition of a 
single labeled nucleotide by primer extension. The primer is fully complementary to 
both alleles, and it is located immediately 3’ of the nucleotide variation site when 
annealing to the target sequence. Therefore, it is assumed that primer extension occurs 
only when the introduced labeled nucleotide is complementary to the nucleotide on 
DNA template at the variation site. As the nucleotide used lacks the 3’-hydroxyl 
group, the extension product cannot extend further after addition of the first base. The 
extension products, which are one base longer than corresponding primers, are then 
analyzed to determine the identity of the incorporated base at the polymorphic site 
based on the fluorescent label (Pastinen et al. 1996, Lindroos et al. 2001, Shi 2001), 
or other moieties (Sokolov 1990, Syvänen et al. 1990, Nikiforov et al. 1994), which 
link to the added nucleotide. 
As both mutant and wildtype alleles are co-amplified with the same efficiencies in 
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the amplification step of this technique, the amplification product derived from the 
mutated template is not enriched in comparison to that derived from wildtype 
template. As a consequence, if the concentration of the wildtype template vastly 
exceeds that of the mutation, the amplification product of mutations might be below 
the detection limit even at the plateau phase of PCR. Although the error rate of Taq 
DNA polymerase is in the range 10-4 – 10-5, the sensitivity of minisequencing to 
detect a low-abundance sequence variant, in reality, is at least one order of magnitude 
lower than the theoretical values.	  
4.2.	  Mutation	  detection	  based	  on	  DNA	  ligase	  	  
This technology is based on the ability of a DNA ligase to join two oligonucleotides, 
which are hybridized to a complementary DNA strand, and are located immediately 
adjacent to each other. In a typical assay, the 3’ end of the first primer is designed to 
locate at the targeting variation site, which is immediately adjacent to the 5’ end of 
the second primer. It is assumed that ligation of these two primers by a DNA ligase 
(e.g., T4 DNA ligase) occurs only when the 3’ end of the first primer matches 
perfectly with the nucleotide at the variation site on target DNA, and a mismatch 
would result in no ligation product. As a consequence, the genotype can be inferred 
by detection of ligation products (Alves et al. 1988, Landegren et al. 1988). 
Originally, there was no enrichment or amplification step involved in these methods, 
so that each assay usually required a large DNA template amount of at least 10 µg. 
More recently, numerous modifications of this technology have been devised to 
combine with other amplification techniques, such as PCR (Shi et al. 2004); 
accordingly, it requires much less DNA template, which opened many more 
possibilities for application. Ligase Chain Reaction (Abravaya et al. 1995) has also 
been exploited to selectively amplify certain alleles, thus resulting in the selective 
enrichment of low-abundance mutations. Alternatively, the ligation may be achvieved 
within a padlock probe, both the 3’ and 5’ ends of which are perfectly matched to the 
target allele, to form a circular DNA, which serves as the perfect template for rolling 
circle amplification in the following step (Lizardi et al. 1998, Nilsson et al. 2000, 
Larsson et al. 2010). These modifications strengthen the capacity of this technology in 
enrichment of low-abundance mutations, and make it feasible for detection of rare 
mutations in excess of wildtype and even allow for visualization of single-molecule 
point mutations in-situ (Larsson et al. 2010). 
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4.3.	  Mutation	  detection	  based	  on	  DNA	  hybridization	  	  
The principle of this method is based on the difference in melting temperatures 
between perfectly matched and mismatched duplexes of target DNA/oligonucleotide 
probe. Depending on the length, sequence and mismatch type of particular duplex, 
this difference in Tm can be in the range of ჼ5–7.5 °C, which is sufficient for the 
specific detection of single nucleotide substitutions in DNA by oligonucleotide probe. 
Normally, either target DNA or oligonucleotide probes in the hybridization reaction 
are immobilized to a solid support, but it is possible to perform solution-based 
hybridization, followed by immobilization in the following step (Dahlen et al. 1993). 
During a stringent washing step at high temperature, the mismatched duplex with 
lower Tm will be disrupted, and washed away. As a result, only the duplex of 
oligonucleotide probe fully complementary to target allele remains to be bound and 
detected, thus indicating the identity of the nucleotide under investigation. This 
method was originally performed with restriction fragments of target DNA, which 
need to be separated and then immobilized on membranes (Wallace et al. 1981). More 
recently, specific fragments of the target sequence (both mutant and wildtype 
sequences) have been enriched by PCR amplification; therefore, it is also amenable to 
immobilization of target DNA without separation by gel electrophoresis (dot blot). In 
a slightly different and more advanced setup, it has been possible to immobilize 
different probes to a membrane (reverse dot blot), which allows for detection of 
multiple mutations in the same reaction (Saiki et al. 1989). Cross-hybridization to 
unexpected DNA variants is a common problem in allele-specific hybridization, 
which necessitates an optimal and accurate control of hybridization, specific washing 
conditions for each application, and a relatively low selectivity. (Farr et al. 1988). 
In summary, majority of mutation detection strategies are directly applicable to 
detect mutation from DNA samples. Although various DNA mutation detection 
assays can identify the presence of specific mutations, the expression level of the 
mutant alleles of coding genes may vary (Yan et al. 2002) and affect the phenotype of 
cells or tissues harboring these mutations. As a result, a sensitive and quantitative 
assay for analysis of mutant RNA transcripts could more accurately reflect the effect 
brought upon the cells or tissues by the presence of a specific mutation. In addition, 
such an assay to analyse mutations from RNA samples is also beneficial for 
epigenetic studies, such as analyses of allele-specific gene expression, RNA editing 
and for detection of clinically relevant mutations within viral genomes, such as drug-
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resistance mutations within infectious diseases caused by HIV and influenza viruses. 
For mutation detection from RNA samples using current technologies, they first need 
to be reverse transcribed non-specifically in to cDNAs, which are later subjected to a 
DNA-based mutation detection assay. 
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AIMS OF THE PRESENT STUDY 
The aim of this study was to utilize molecular biology knowledge to develop novel 
amplification-based technologies, which would be powerful for detection of 
challenging nucleic acid targets, including those with extremely long, GC-rich and/or 
repetitive sequences and point mutations at very low abundance in the excess of 
wildtype templates. Different inherited diseases, malignant and non-malignant 
diseases have been employed as models for the purpose of method development and 
validation. The specific aims of this study were: 
1) To develop a universal strategy for effective amplification of particular nucleic 
acid sequences that are refractory to conventional PCR due to great amplicon 
length, high GC content and/or repetitive nature, and for reducing amplification 
bias. 
2) To develop a PCR-based method for detection and characterization of full-
mutation Fragile X repeat expansions. 
3) To develop and validate a PCR-based method for detection and sizing analysis of 
(CTG) repeat expansion in Myotonic Dystrophy type 1 disease. 
4) To develop a universal approach to achieve allele-specific priming with high 
selectivity during reverse transcription, thus allowing for sensitive detection of 
low-abundance expressed mutations. 
5) To develop a PCR-based method for ultrasensitive, convenient and flexible 
detection of KRAS mutations at the RNA level. 
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MATERIALS AND METHODS 
1. PATIENTS AND SAMPLES 
1.1.	  DNA	  samples	  
! DNA samples extracted from Fragile X cell lines (I): Fragile X cell line DNA 
samples, which serves as experimental model showing the proof of principle 
of the method, were kindly provided by Finnzymes Oy (Vantaa, Finland, now 
part of Thermo Scientific). They were originally obtained from Coriell Cell 
Repositories (Coriell Institute for Medical Research). All DNA samples were 
quantified using a NanoVue spectrophotometer (GE Healthcare, Waukesha, 
WI) and diluted to 10 ng/µL in distilled H2O, which serve as the PCR 
templates. 
! DNA samples extracted from DM1 patients (II): Human genomic DNA had 
been extracted from DM1 patients’ EDTA blood or placental tissue samples, 
which are used as template for method development and validation. These 
samples consisted of two sample sets: the first set is extracted during the years 
2004-2008 (N=78), initially analyzed by Southern blotting and then re-
analyzed by HPE-PCR in this study; the second set is extracted during the 
years 2009-2012 (N=57), analyzed by HPE-PCR only. All DNA samples were 
diluted to 10 ng/µl in distilled H2O, prior to the PCR and the use of the sample 
is ethically approved for this purpose within the institution. 
! Healthy DNA samples (I, II): Human genomic DNA was extracted from 200 
µL of healthy whole blood using a QIAamp DNA Blood Mini Kit (QIAGEN 
GmbH, Hilden, Germany). 
1.2.	  RNA	  samples	  (III)	  
! In-vitro transcription RNA samples: RNA templates used for assay 
development and validation have been generated by in-vitro transcription 
(AmpliScribe™ T7, T3, and SP6 High Yield Transcription Kits, Epicentre 
Biotechnologies). DNA templates for in-vitro transcription are generated from 
synthetic DNA template using PCR amplification with Phusion High-Fidelity 
DNA polymerase (Finnzyme, Vantaa, Finland, now part of Thermo 
Scientific). The synthetic DNA oligonucleotides were obtained from TAG 
Copenhagen A/S, each oligonucleotide was about 100 nucleotides in length, 
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including 20 nucleotides of T7 promoter’s sequence (in bold) at the 5’ end and 
the rest corresponding to the wildtype or different mutated variants of the 
KRAS and BRAF genes. (III, Table 1).  
The concentrations of in-vitro transcribed RNA samples were quantified using a 
NanoVue spectrophotometer (GE Healthcare, Waskesha, WI), and verified using 
quantitative RT-PCR (Tetro cDNA synthesis kit and SensiFAST™ SYBR No-ROX 
Kit, Bioline) with primers listed in Table 2 of III. 
! Human RNA samples: Human RNA samples from colorectal cancer tumor 
tissue were extracted from formalin-fixed paraffin embedded (FFPE) samples 
using phenol-chloroform extraction (Stenman et al. 2006). These samples 
were used as templates in the examples of utility of the ExBP-RT assay. The 
institutional review board approved the use of clinical samples for this 
purpose. All RNA samples were measured using a NanoVue 
spectrophotometer (GE Healthcare, Waskesha, WI) and they are diluted to 500 
ng/µl in DEPC H2O for use as templates in the allele-specific reverse 
transcription reaction. 
! RNA samples extracted from cell lines: RNA samples were extracted from 
cell line A549 harboring mutated KRAS gene and cell line COLO205 
containing KRAS wildtype gene for mutation and wildtype control in ExBP-
RT assays (III) 
1.3.	  Primer/probe	  design	  and	  oligo	  synthesis	  (I,II,III)	  
Primer design and analysis was performed with the aid of the commercial software 
(Oligo primer analysis software 6.8, Molecular Biology Insights, Inc, USA). The 
optimal primers were selected to have sufficient priming efficiencies (PE), and not to 
form stable hairpin, primer dimer or cause significant false priming. 
The melting temperature (Tm) is calculated using DINAMelt Web Server / Two 
State Melting (hybridization), which is available at the following link: 
http://mfold.rna.albany.edu/?q=DINAMelt/Two-state-melting. This Tm prediction 
platform is based on the “unified” oligonucleotide nearest-neighbor parameters 
(SantaLucia 1998). 
All primers were ordered from TAG Copenhagen A/S, Sigma Oligo or IDT with 
HPLC purification. 
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2. HEAT PULSE EXTENSION PCR (HPE-PCR) FOR 
AMPLIFICATION OF LONG, GC-RICH AND/OR REPETITIVE 
SEQUENCES (I,II) 
2.1.	  Comparison	  of	  HPE-­‐PCR	  to	  existing	  PCR	  cycling	  protocols	  for	  
amplification	  of	  difficult	  sequences	  and	  Fragile	  X	  repeat	  expansions	  (I)	  
In order to test the performance of HPE-PCR, conventional PCR with a constant 
extension temperature was performed and compared with amplification using a Heat 
Pulse Extension PCR protocol (Table 2, I). Both cycling protocols share an initial 
denaturation step at 94°C for 7 minutes, followed by 35 cycles with a two-stage 
denaturation step (94°C for 45 seconds and 98°C for 10 seconds), a primer annealing 
step at a template-specific estimated optimal annealing temperature for 30 seconds, 
and an extension step. The conventional cycling protocols for amplification of the 
Fragile X sequences were performed with extension steps at a constant temperature of 
72°C, 78°C or 83°C, in order to compare with HPE-PCR protocol, which is 
characterized by an extension step with fluctuating temperatures (I, Figure 1) 
We also performed benchmarking experiments with other recently reported PCR 
cycling protocols for amplification of GC-rich sequences, including Slowdown PCR 
(Frey et al. 2008), Hotstart & Touchdown PCR (Hube et al. 2005) and SAFE PCR 
(Wei et al. 2010) according to the protocols described in the original reports.  
2.2.	  HPE-­‐PCR	  cycling	  conditions	  for	  amplification	  of	  (CTG)	  repeat	  expansion	  
in	  DM1	  (II)	  
PCR amplification was performed on a GeneAmp 9700 thermal cycler (Applied 
Biosystems, Foster City, CA) with 96-well PCR plates. The sample volume parameter 
was set to minimum (5 µl) to minimize block temperature overshoot. The initial 
denaturation was for 7 min at 94 °C, followed by 40 cycles of HPE-PCR of three 
steps: denaturation, primer annealing and extension (II, Table 1 and Figure 1) 
The denaturation step was 45 s at 95 °C, followed by rapid raise to 98 °C for 10 s. 
Primer annealing took place at 68 °C for 30 s. The extension step started by gradual 
heating to the basal extension temperature of 76 °C (30 % ramp rate), then multiple 
heat pulses were introduced sequentially. Each heat pulse consisted of gradual heating 
to the peak extension temperature 83 °C and rapid cooling to the basal extension 
temperature. These heating pulses were repeated 21 times during each PCR extension 
step. 
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2.3.	  Touchdown	  PCR	  and	  fragment	  analysis	  of	  DM1	  repeats	  (II)	  
For accurate sizing analysis of normal length repeats with high resolution on a 
DNA sequencer, a FAM-labelled PCR primer is used and PCR products are subjected 
to fragment analysis using Genetic Analyzer 3130xl (Applied Biosystems, Foster 
City, CA). The touchdown PCR cycling protocol includes initial denaturation at 94 °C 
for 10 min; 20 PCR cycles with annealing temperature decreasing from 68 °C to 
60 °C by -0.4°C per cycle; and 16 additional PCR cycles at 95 °C for 1 min, 60 °C for 
1 min, 72 °C for 3 min; and a final extension at 72 °C for 10 min. 
2.4.	  Agarose	  gel	  electrophoresis	  (I,II)	  
Ten µL of PCR products were mixed with 2 µL of 6x loading dye (Fermentas) and 
run on 1% agarose gels in TBE buffer with a 1 kb DNA Ladder (I,II) until sufficient 
separation. Gels were stained with the SYBR Gold Nucleic Acid Gel Stain or SYBR 
Safe (10,000 X, Invitrogen) and gel images were taken by AlphaImager®Mini system 
(Alpha Innotech). 
2.5.	  DNA	  sequencing	  and	  fragment	  analysis	  (I)	  
We sequenced the gel-purified PCR products using service provided by the Institute 
for Molecular Medicine, Finland (FIMM, P.O. Box 20, FI-00014 University of 
Helsinki, Finland). DNA alignments were conducted with BLAST/blastn application 
from NCBI.  
To further confirm the identity of different Fragile X expansions amplified by HPE-
PCR, we digested the amplification products with the restriction enzyme EcoN1 (New 
England Biolab), which cuts the double-stranded DNA containing the sequence 5’ 
…CCTNNNNNAGG… 3’ present in all Fragile X expansion amplicons in this study, 
to generate a fragment of about 110 bp and the other fragment of varying length. 
2.6.	  Southern	  blot	  analysis	  (II)	  
We applied six µg genomic DNA for digestion with 10 U Bam HI (Amersham 
Pharmacia Biotech, Buckinghamshire, UK) over night at 37°C. Fragments separated 
on 0.8% SeaKem Agarose gel (FMC, Rockland, ME) were transferred to Hybond-N 
nylon membrane (Amersham, UK). The filter was depurinated, denatured and 
neutralized using routine methods.  
A 1.4 kb Bam HI fragment cloned in Blue Script vector serves as the probe. After 
being cut and purified (Nick Spin Columns, Amersham Pharmacia Biotech, Sweden), 
the insert was labelled with 32P-dCTP and 32P-dGTP using a Klenow fragment of 
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DNA polymerase (Random Primed DNA Labelling Kit, Roche). The Human Cot-1 
DNA (Gibco BRL) was used to block repetitive sequences, and the blocked probe 
was allowed to hybridize with the filter in hybridization buffer overnight at 65°C. 
After stringent wash, we detected the labelled fragments using BIOMAX-TM 
imaging film (Kodak). 
 
3. DETECTION OF LOW-ABUNDANCE EXPRESSED MUTATIONS 
(III) 
3.1.	  Extendable	  blocking	  probe	  –	  reverse	  transcription	  (ExBP-­‐RT)	  
The ExBP-RT assay consists of both a mutation-specific primer, which targets the 
mutant RNA, and a wildtype-specific blocking probe, which was designed to target 
the wildtype RNA (sequences of primers and probe listed in III, Table 3). Unlike the 
wildtype-specific blocking probe, the mutation-specific primers contain a nuleotide 
tail at the 5’ end of non-related sequence, which generated a priming site for the 
subsequent amplification reactions. 
We assembled 10-µL cDNA synthesis reactions according to the manufacturer’s 
instruction, except for adding the enzyme reverse transcriptase (Tetro Reverse 
Transcriptase, Bioline, London, UK). The thermal program includes 65 °C for 5’, 
then cooling down to 50 °C and adding reverse transcriptase enzyme (manual hotstart 
of reverse transcription). The reaction temperature was then decreased by 1 °C every 
1 minute to 37°C. Finally, enzyme reverse transcriptase was inactivated at 85 °C for 5 
min and the cDNA products were stored at -20 °C for later analysis.  
In multiplex ExBP-RT assays, we used six different mutation-specific primers 
targeting all possible KRAS mutations at codon 12 and a common Extendable 
Blocking Probe targeting the wildtype KRAS transcript in the same reaction of 
reverse transcription. Because many primers and an Extendable Blocking Probe are 
included in a single reaction of multiplex ExBP-RT, we adjusted the optimal 
concentration of Mg2+ ion to 10 mM. In addition, digestion of free primers and 
nucleotides were performed using 10 unit of Exonuclease I (Thermo Scientific) and 1 
unit of Thermosensitive Alkaline Phosphatase (Thermo Scientific) after cDNA 
synthesis. 
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3.2.	  Quantitative	  PCR	  
Quantitative PCR reactions (SensiFAST™ SYBR No-ROX Kit, Bioline or 
SensiFAST™ Probe No-ROX Kit, Bioline for probe-based detection) were performed 
using 1 µL of cDNA products as templates. The PCR cycling program included 95 °C 
for 2 min, then for 42 cycles at 95 °C for 5 s, 63 °C for 20 s and 72 °C for 10 s. In 
multiplex ExBP-RT, 1 µL of each cDNA synthesis product were amplified in the 
10µL qPCR reactions using QuantiTect SYBR PCR Kits (Qiagen) at 95°C for 15 min, 
then 45 cycles at 94°C for 15 s and 60°C for 45s, for detection of either mutant or 
total KRAS transcripts. Primer and probe sequences for each qPCR assay are listed in 
III, Table 4. We performed all qPCR assays on a LightCycler 480 II Real-Time PCR 
Instrument (Roche Diagnostics Oy, Finland) using 384-well thermal block. The 
specificity of the amplification products was always verified after SYBR-based qPCR 
by melting curve analysis. All reactions were run in duplicate or higher replication 
where specified, and all replicates went through both ExBP-RT and qPCR steps. 
Amplification efficiencies of 100% are confirmed for all qPCR assays used in this 
study. 
3.3.	  ASB-­‐PCR	  (Allele-­‐Specific	  Blocker	  PCR)	  
ASB-PCR begins with a 10-µL reverse transcription reaction using Tetro Reverse 
Transcriptase (Bioline, London, UK) according to the manufacturer's instructions. In 
the PCR step, 1 µL of cDNA product was used as template in a 10-µL reaction of 
qPCR containing 1× TaqMan® Universal Master Mix II, no UNG (Applied 
Biosystems, Foster City, CA), 900 nM primers, 200 nM probe and 3600 nM blocker. 
PCR thermocycling conditions included: 95°C for 10 min, 40 cycles at 95°C for 20 
sec, at 60°C for 45 sec. The oligonucleotide sequences used for KRAS G12D 
mutation assays has been in accordance with the assay Mut2.1 within the original 
publication (Morlan et al. 2009), which includes Forward mutation-specific primer: 
tgtggtagttggagctga; Reverse primer: tgattctgaattagctgtatcgtcaa; Blocker: 
ttggagctggtggcgtagg-PO4; and Taqman probe: FAM- cac+Tc+T+Tgcctacgc-BHQ1 
(+N stands for LNA nucleotide). Each ASB-PCR assay was run in duplicate on the 
same system as with ExBP-RT assay. 
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4. DATA ANALYSIS (III) 
The built-in analysis software of the LightCycler® 480 II system (Roche 
Diagnostics Oy, Finland) automatically calculates the values of threshold cycle (Ct) 
for each assay using the default second derivative maximum method. 
Ideally, a mutation detection assay should only generate a signal with matched 
template (mutant RNA) but generate no signal with mismatched templates (wildtype 
RNA). In reality, mismatched templates often produce some signal level, which is 
characterized by the selectivity of a mutation detection assay. In this study, we 
adopted the definition of selectivity that has been used in different published studies 
(Liu et al. 2004, Morlan et al. 2009). Selectivity of a mutation detection assay is the 
relative response of that assay to matched and mismatched templates, and it is often 
expressed as ratio or percentage. For example, an assay that can detect 1 mutant 
template in the presence of 100 wild type templates is said to have a selectivity of 
1:100 or 1%. 
More specifically, the selectivity in our study was determined by comparing 
products formed in a first reaction containing mismatched template (wildtype RNA) 
with those formed in a second reaction containing the same copy number (107 copies) 
of matched templates (mutant RNA). In reality, if a sample containing the mutant 
RNA template with a fraction as low as the selectivity, the mutant signal will be equal 
to the background signal derived from wildtype RNA. As a result, the signal derived 
from that sample, which is the sum of mutant signal and background signal, will be 
well above the background signal and can be detected. 
The difference in Ct values derived from two qPCR reactions (ΔCtwt-mt = Ctwildtype 
– Ctmutant) form the basis for calculating the ratio of product formed in the first 
reaction normalized against product formed in the second reaction. We calculate the 
selectivity of each ExBP-RT assay expressed as percentage using the formula 2-ΔCt x 
100%. This percentage corresponds to the lowest fraction of mutant transcripts to be 
detected as a distinct signal from the background signal derived from the wildtype 
template. 
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RESULTS AND DISCUSSION 
1. HEAT PULSE EXTENSION ENABLING PCR AMPLIFICATION 
OF LONG, GC-RICH AND/OR REPETITIVE DNA (I,II) 
1.1.	  Principles	  of	  Heat	  Pulse	  Extension	  Polymerase	  Chain	  Reaction	  (HPE-­‐PCR)	  
We introduced multiple heat pulses during the PCR extension step to generate a 
novel cycling protocol, named Heat Pulse Extension Polymerase Chain Reaction 
(HPE-PCR). It was hypothesized that these heat pulses would temporarily destabilize 
secondary structures (Figure 5), thus allowing for DNA polymerase to extend 
completely over long, GC-rich and/or repetitive sequences, and subsequently increase 
amplification efficiency of such sequences. 
 
  
Figure 5: Illustrative temperature profile in each cycle of HPE-PCR with multiple 
heat pulses (in “orange”) during the extension step to temporally stabilize secondary 
structures, such as stable hairpins (A); quadruplexes (B); or re-annealed/incomplete-
denaturation duplexes (C). (DNA target strand in “blue”, primer or complementary 
strand in “red”; and DNA polymerase in “turquoise”) 
 
In contrast to conventional PCR where the extension step is performed at a constant 
temperature, the HPE-PCR extension step starts by gradual heating to a basal 
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extension temperature in the range 72-80°C, then the reaction temperature fluctuates 
between a peak temperature in the range 80-90°C and the basal extension temperature 
for multiple times (heat pulses). The number of heat pulses needed for efficient 
amplification is dependent on the length, sequence and GC-content of the DNA 
template. In this study, 14 - 21 heat pulses were sufficient for effective amplification 
of all long, GC-rich and/or repetitive sequences that are normally refractory to PCR 
amplification (I,II) 
The commonly used PCR extension temperature (72°C) might not be optimal for 
destabilizing stable secondary structures and high-melting-temperature duplexes, 
which would potentially block extension by DNA polymerases (Chou 1992, 
McDowell et al. 1998). In order to prevent complete dissociation of partly extended 
strands from their templates during the extension step of an HPE-PCR protocol, the 
hold times for the peak temperatures were relatively short; 0 – 2 seconds, ramping 
rates were set at maximum and primers were designed to locate several hundred bases 
away from the difficult GC-rich regions. 
The HPE-PCR cycling protocol is typically longer than conventional PCR 
protocols, but comparable to Slowdown PCR protocols of about 4 - 6 hours, 
depending on the number of heat pulses introduced in each extension step. The 
lengthened cycling time consists both the extension time at a basal temperature and 
the time spent on fluctuation of extension temperatures that is dependent on the 
maximal ramp rate of the thermal cycler used. 
Almost all previous approaches to optimization of PCR for amplification of GC-
rich sequences focus on the annealing step (Schuchard et al. 1993, Bachmann et al. 
2003, Hube et al. 2005, Frey et al. 2008), in order to reduce non-specific priming in 
order to compensate for low extension efficiency over difficult target sequences. 
These approaches, however, are not efficient enough, if the target sequences have a 
tendency to form exceptionally stable secondary structures. It is also apparent that 
optimization of the annealing step will not change the relative amplification 
efficiencies between PCR templates that share the same priming sites, thus being 
primed with same efficiency. As a consequence, the shorter and/or less GC-rich 
sequences will be extended more efficiently, and as a result, dominate the 
amplification reaction. In contrast, the efficiency of the extension step is targeted in 
the HPE-PCR cycling protocol, so that it minimizes the differences in amplification 
efficiencies between target templates of varying length and GC-content. 
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Consequently, this novel cycling protocol allows for amplification over challenging 
sequences as well as amplification with reduced bias caused by differences in length 
and GC-content that are clarified in the results described below. This technique might 
be useful in numerous applications including quantitative competitive PCR, multiplex 
PCR, bisulfite-based cytosine methylation analysis and different applications related 
to amplification of nucleic acid libraries, that are hampered by amplification bias 
(Warnecke et al. 1997, Polz et al. 1998, Voss et al. 1998, Kanagawa 2003, Aird et al. 
2011). 
1.2.	  HPE-­‐PCR	  enabling	  amplification	  of	  extremely	  long	  (GGC)	  repeats	  in	  
Fragile	  X	  syndrome	  
A panel of Fragile X cell lines containing different repeat expansions (from 23 to 
940 GGC repeats) were used as a model to generate proof of concept for the HPE-
PCR cycling protocol using standard PCR reagents with primer sequences listed in 
Table 1, I. 
All full-mutation expansions in the Fragile X cell lines under investigation were 
detected using the HPE-PCR cycling protocol, including the longest expansion of 940 
GGC repeats (NA09237), which corresponds to a 2.8-kb segment of 100% GC (I, 
Figure 2A and Figure S1-5). The extremely long full-mutation expansions could not 
be detected by conventional PCR using the same reagents and extension at 72°C (I, 
Figure 2B), and at the same time, multiple non-specific products showed up as we 
expected for typical PCR amplification of GC-rich sequences (Mamedov et al. 2008). 
PCR assays with a constant and elevated temperature of either 78°C or 83°C during 
extension step also failed to amplify the large expansion repeats and non-specific 
products were still formed (I, Figure-S6A&B). The extension temperature of 83°C is 
too high for DNA polymerase extension activity, as only a faint band for each wild 
type unexpanded allele was detected (I, Figure-S6B). Since both conventional PCR 
and HPE-PCR cycling protocol share the same denaturation and annealing steps, it is 
conceivable that the improved performance of the HPE-PCR protocol is attributed to 
multiple heat pulses during extension, which improved extension over difficult GC-
rich segments. 
Furthermore, the HPE-PCR cycling protocol allows for amplification of the large 
repeat expansions, even in the presence of the wildtype-unexpanded allele in different 
heterozygous cell lines (NA07537, NA06896, NA20239) (I, Figure 2A: lane 3,5,6). 
This is in contrast to the conventional PCR cycling protocol, which showed strong 
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amplification biases favoring the shorter wild type allele, and the expanded alleles 
being completely lost in all amplification products derived from heterozygous cell 
lines (I, Figure 2B: lane 3,5,6 and Figure-S6A&B: lane 3,5,6, in Supporting 
Information). This improvement indicates that the HPE-PCR cycling protocol 
facilitates the balance of amplification efficiencies between multiple templates with 
different lengths and GC contents.  
In addition to multiple heat pulses, the co-solvent betaine seems to be critical for the 
improved performance of HPE-PCR, because we were not able to amplify the longest 
expanded Fragile X alleles (940 repeats) in the absence of this co-solvent (I, Figure 
2A: lane WO). Interestingly, another commonly used additive DMSO (5%) did not 
result in a corresponding favourable effect (I, Figure 2A: lane DMSO). We have 
speculated that the betaine’s iso-stabilizing effect improves the stability of both the 
DNA and the DNA polymerase molecules (Melchior et al. 1973, Nash et al. 1982, 
Rees et al. 1993) during the extension step with multiple heat pulses. Although we 
have not extensively studied the possible beneficial effect of any other additives and 
their combinations, it seems reasonable to continue exploring this path in order to 
futher increase the capacity of the HPE-PCR cycling protocol for amplifying very 
long GC-rich sequences, as implied in a recent study by Filipovic-Sadic et al. 
(Filipovic-Sadic et al. 2010). 
1.3.	  HPE-­‐PCR	  for	  detection	  and	  sizing	  of	  large	  (CTG)	  repeats	  in	  DM1	  
The HPE-PCR cycling protocol enables amplification of large (CTG) repeat 
expansions in Myotonic Dystrophy type 1, and the amplification products detected on 
agarose gel is in complete concordance with Southern blotting analysis as illustrated 
in II, Figure 3. On Southern blot analysis, a large homogenous expansion of about 
1400 CTG repeats was detected as a specific band from a patient with congenital 
DM1 (II, Figure 3A, sample C), and a heterogeneous expansion of similar size was 
visualized as a smear showing multiple fragments of slightly different lengths from a 
patient with adult onset DM1 (II, Figure 3A, sample A). These results were 
reproduced by HPE-PCR (II, Figure 3B), where both the short wildtype allele and the 
expanded allele from the congenital DM1 sample were detected on agarose gel 
stained with ethidium bromide as two distinct specific bands with close-to-equal 
amplification efficiency (II, Figure 3B sample C). The heterogeneous expansion was 
also detected from the adult-onset DM1 sample as smear similar to that seen in the 
corresponding Southern blot analysis (II, Figure 3A and 3B, sample A). Gel image of 
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HPE-PCR products seemed to have less background signal and more clear bands than 
that of the corresponding Southern blot results. 
The performance of HPE-PCR cycling protocol for amplification of large (CTG) 
repeats in DM1 was validated using a collection of samples (N=78), which represent a 
wide range of CTG-repeat lengths and a varying degree of tissue heterogeneity. All 
samples were originally analyzed for DM1 by Southern blotting and re-analyzed with 
the HPE-PCR assay. The HPE-PCR results and Southern blot analysis were fully 
concordant with each other (II, Table 2), showing similar sizes of the largest 
expansions and the same degree of expansion heterogeneity, which is characterized 
by extra bands or smears of shorter repeat expansions. There would be no diagnostic 
error if the original analysis had been based on HPE-PCR rather than on Southern 
blotting. As an illustration, the HPE-PCR amplification products derived from 18 
samples with the longest CTG expansions and 1 sample of the healthy individual are 
presented in II, Figure 2. While the unexpanded alleles were detected as bands of 
about 350 bp, all expanded alleles up to 1750 (CTG) repeats could be detected using 
HPE-PCR, even alleles with high degree of heterogeneity (marked with “*” in II, 
Figure 2). In our analysis of over 120 diagnostic patient samples, HPE-PCR only 
failed to amplify a gigantic expansion of about 2500 repeat units from only one 
placental sample of a DM1 patient. 
Although PCR-based methods are more cost-effective, high-throughput and 
require less DNA sample (Radvansky et al. 2010), Southern blot analysis still serve as 
the gold standard for molecular diagnostics of DM1 due to challenges of PCR to 
successfully amplify these long and complex templates (Cheng et al. 1996, Pearson et 
al. 1996). Although there are a number of modifications to PCR reaction reagents or 
cycling protocols for PCR-based detection of repeat expansions in DM1 (Cheng et al. 
1996, Gennarelli et al. 1998), these improvements are usually not sufficient for 
amplification of the expansions of more than 80-100 (CTG) repeats. In addition to the 
increased cost and reduced throughput, modifications often make the analytical 
procedure more complex. For example, substitution of dGTP for 7-deaza-dGTP 
interferes with gel staining using intercalating-dyes, and requires probe-mediated 
detection and/or Southern blot transfer of PCR products. Another disadvantage of 
these modified methods is the low resolution since the flanking primers need to be far 
away from the actual repetitive loci and the PCR product corresponding to normal 
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alleles is about 2.1 kb (Skrzypczak-Zielinska et al. 2009), which is much longer than 
400 bp when using the HPE-PCR technique. 
 
2. EXTENDABLE BLOCKING PROBE – REVERSE 
TRANSCRIPTION FOR ENRICHMENT OF LOW-ABUNDANCE 
EXPRESSED MUTATIONS (III) 
2.1.	  Principles	  of	  extendable	  blocking	  probe	  –	  reverse	  transcription	  (ExBP-­‐
RT)	  
We devised a novel approach for mutation detection using RNA samples as 
templates, named extendable blocking probe – reverse transcription, which employs 
an “extendable” competitive blocking probe to neutralize the wildtype RNA transcript 
during reverse transcription; therefore, the rare mutant RNA transcript is selectively 
primed by the mutation-specific primer to form mutant cDNA and cross priming is 
efficiently blocked (Figure 6). As a result, the rare RNA variant (e.g. mutation) can 
be detected in at least a 1000-fold excessive background of the alternative variant 
(e.g. wildtype). In contrast to almost all existing mutation detection technologies, 
where RNA needs to be reverse transcribed into cDNA prior to an actual DNA-based 
mutation detection assay, ExBP-RT technology directly transforms RNA variants 
with minor differences, such as single-base substitutions, into allele-specific products 
that are easily distinguishable using a single reaction of reverse transcription. 
 
Figure 6: Schematic of ExBP-RT assay in combination with qPCR for detection of 
mutation from RNA sample with superior selectivity. Mutation-specific primer (with 
5’ tail) and wildtype-specific primer (without 5’ tail) compete successfully to prime 
on the corresponding RNA templates in ExBP-RT assay. The mutation-specific 
cDNA containing the 5’ tail is selectively amplified in qPCR amplification step.  
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In the ExBP-RT assay, the mutation-specific primer and wildtype-specific 
Extendable competitive Blocking Probe, which contain priming sequences fully 
complementary to mutant and wildtype RNA respectively, are both present in the 
reverse transcription reaction (III, Figure 1). The hot-start protocol during reverse 
transcription allows the correct priming to occur at substantially higher temperature 
and temporally prior to mispriming. When the reaction temperature is cooled down 
slowly towards the optimal temperature for primer annealing, the mutation-specific 
primer selectively initiates cDNA synthesis on the mutant RNA template to form the 
mutant cDNA product. At the same time, the extendable blocking probe initiates 
cDNA synthesis on the wildtype template to form a wildtype RNA-cDNA hybrid. 
This wildtype hybrid, which is of much greater length than the original probe, 
efficiently blocks the site available for cross priming; therefore, the mutation-specific 
primer cannot bind to the wildtype RNA template when the temperature is decreased 
to a level where cross priming could potentially occur.  
Most of currently available strategies for mutation detection utilize DNA 
templates, and follow steps of target DNA amplification; allele discrimination 
reaction; and detection/identification of allele-specific products (Chen et al. 2003). 
Target amplification is normally performed in the first step (Kim et al. 2007). If the 
target amplification step is performed prior to a separate allele discrimination 
reaction, such as mini-sequencing (Syvanen 1999, Matyas et al. 2002, Murphy et al. 
2003), the mutant allele will not be enriched in relation to wildtype one in the 
amplification product, and there is an increased risk of laboratory contamination due 
to the obligatory handling of post-amplification products. On the other hand, when the 
target amplification step coincides with the allele discrimination reaction, such as in 
allele-specific PCR, the allele discriminating power decays during the course of the 
amplification process (Giffard 2001, Chen et al. 2003).  
In contrast, the allele discrimination reaction in ExBP-RT approach occurs during 
reverse transcription; therefore, it does not require a separate step for allele 
discrimination or handling of post-amplification products. Moreover, single-cycle 
reverse transcription reaction with relatively long extension time in ExBP-RT assay 
allow for optimization of the primers solely for allele discrimination, without 
negatively affecting PCR performance. The discrimination between perfect match and 
mismatch have been maximized by designing short priming sequences, which are 
approximately ten nucleotides in length and Tm ≅ 37 °C – 50 °C, according to 
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DINAMelt Web Server (SantaLucia 1998, Markham et al. 2005). These Tm values of 
primers and probes are sufficiently high for the ExBP-RT assay when the lowest 
temperature of the RT protocol is 37°C. Lastly, the allele discriminating power 
achieved during ExBP-RT is unaffected by the following exponential PCR 
amplification as opposed to allele-specific PCR, because the allele discrimination 
reaction occurs before subsequent selective amplification of the target cDNA 
products. As there is a non-related sequence coupled to the 5’ end of mutation-
specific primer, the resulting mutation-specific cDNA product contains a unique 
downstream priming site, which is absent in the wildtype cDNA product. This 
dissimilarity allows for selective amplification of the mutation-specific cDNA product 
by quantitative PCR, while the wildtype cDNA that lacks the primer-binding site for 
the reverse PCR primer (III, Figure 1B) will not be amplified. 
2.2.	  ExBP-­‐RT	  assays	  for	  detection	  of	  RNA	  variants	  with	  superior	  selectivity	  
The improved performance of ExBP-RT assay is most obvious when comparing 
with the corresponding assay not containing any blocking probes. In a model 
experiment using BRAF V600E as template and the same reagents of reverse 
transcription reactions, we have shown that the selectivity of ExBP-RT assay 
(0.017%: III, Figure 3b) is 300 times higher than that of a corresponding assay 
lacking a blocking probe (5%: III, Figure 3a). Using the same model, we further 
showed that the addition of a non-extendable blocking probe just slightly increased 
the selectivity to about 1.8% (III, Figure 3c), which is still 100 times lower than that 
achieved by the ExBP-RT assay containing the extendable wildtype-specific blocking 
probe. This data clearly suggests that the underlying mechanism of ExBP-RT 
involves the initiation of primer extension from the blocking probe upon its 
hybridization to the wildtype template to form a cDNA product; consequently, there 
are no mispriming sites available for the mutation-specific primers to bind when the 
reaction temperature is gradually decreased. This mechanism of function is in contrast 
to the commonly used non-extendable wildtype-specific blocking probes, which 
inhibit cross-priming based on its hybridization to the wildtype template (Seyama et 
al. 1992, Orou et al. 1995, McKinzie et al. 2002, Parsons et al. 2005, Beau-Faller et 
al. 2009, Morlan et al. 2009, Milbury et al. 2011, Smith et al. 2011, Didelot et al. 
2012, Wang et al. 2013). 
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In another model assay for detection of mutant KRAS G12D (GGT>GAT) 
transcript, the selectivity of ExBP-RT (0.04%: III, Table 5), which is attributed 
directly to allele-specific priming at the stage of reverse transcription, was shown to 
be higher than that of another advanced PCR-based mutation detection assay (0.15%: 
III, Figure 3S), which is performed after an initial “non-specific” reverse transcription 
(Morlan et al. 2009). The superior performance of ExBP-RT assay over PCR-based 
assay was even more obvious due to the fact that the most stable primer:template 
mismatch (dT:rG) (Sugimoto et al. 2000) was targeted in the ExBP-RT assay, 
whereas the PCR-based assay (Mut2.1) involve the reasonably unstable 
primer:template mismatch (dA:dC). The selectivity of a PCR-based assay targeting 
the same mutation, but on the other strand (originally named Mut2.2 assay) was 
reported to be even less selective (Morlan et al. 2009), appearently, because it 
involves the most stable primer:template mismatch (dT:dG). 
The superior selectivity of ExBP-RT was also demonstrated using several RNA 
mixtures of the mutant KRAS G12R RNA diluted in the wildtype KRAS transcript 
with different ratios, ranging from 10 down to 10-4 (10, 1, 10-1, 10-2, 10-3, 10-4). It was 
shown that mutant KRAS G12R RNA was detected as a signal distinct from the 
wildtype KRAS RNA in mixtures containing a proportion of 1:1,000 or more of 
mutant KRAS G12R RNA (III, Figure 2a) and the detection was linear from 1:1000 to 
10:1 (III, Figure 2b, r2=0.9955, least-squares analysis). We also visualized 
amplification products on agarose gel 2% and confirmed the expected size (59 bp) of 
amplified sequences (III, Supplementary Figure 2S). There was no amplification in 
negative controls lacking RNA template, mutation-specific primer or reverse 
transcriptase. 
We further investigated the selectivity of the ExBP-RT assays on a number of 
different templates and mutation types, including all six possible mutations at codon 
12 of the KRAS gene and the BRAF V600E mutation (III, Table 3). The selectivity 
expressed as percentage of each ExBP-RT assay is 2-ΔCt x 100%. The ExBP-RT assays 
were able to detect different mutant KRAS or BRAF RNAs in the presence of 1000 to 
6,000-fold more excessive background of wild type transcripts at a selectivity ranging 
from 0.017% to 0.09% (III, Table 5). In contrast to allele-specific PCR where it is 
required to optimize carefully PCR reaction conditions for sufficient sensitivity 
(Newton et al. 1989, Wu et al. 1989, Cha et al. 1992, Fox et al. 1998, Clayton et al. 
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2000, Latorra et al. 2003, Strerath et al. 2004, Sapio 2006, Toni et al. 2010, Zhou et 
al. 2011), it was relatively simple to set up ExBP-RT assays without massive 
optimization. A universal protocol can be applied for detection of all mutation types 
on the different genes tested. In addition, the selectivity of ExBP-RT assays, which 
ranged from 10-3 – 10-4, seemed to be less influenced by the nature of polymorphisms 
and surrounding sequences in comparison to AS-PCR (Chen et al. 2003). Even the 
most stable primer:template mismatch (dT:rG) (Sugimoto et al. 2000) resulted in a 
sufficiently good selectivity in ExBP-RT assays for detection of KRAS G12D 
(GGT>GAT) and KRAS G12S (GGT>AGT) mutations, of 4x10-4 and 9x10-4, 
respectively. 
2.3.	  Detection	  of	  KRAS	  mutations	  in	  FFPE	  samples	  
We investigated whether the ExBP-RT assay was applicable for detection of 
mutation within RNA extracted from challenging samples, such as formalin-fixed 
paraffin embedded samples. Moreover, different detection platforms, based on either 
SYBR Green I or a sequence-specific probe, were explored in the quantitative PCR 
step following ExBP-RT assay. We exploited a model assay for detection of the most 
common KRAS mutation type (G12D), which accounts for approximately 32.5% of 
all KRAS mutations (Normanno et al. 2009), from FFPE samples of colorectal cancer 
patients. Of 11 FFPE samples used as a template for the ExPB-RT assay, one sample 
was clearly positive for the G12D mutation on both probe – based qPCR (III, Figure 
4) and SYBR Green I – based qPCR. We further confirmed the specific band of 
expected size for the tested positive sample and no specific band detected for all the 
tested negative samples on agarose gel plot (III, Figure 5S). In this example of utility, 
we included also the positive control of mutant RNA (107 copies), which showed 
early amplification (left red curve), and negative controls without RNA template or 
reverse transcriptase, which showed complete lack of amplification. Moreover, we 
quantified and confirmed that the amounts of total KRAS RNA in different clinical 
samples were comparable (0.6 – 1.8 x 105 copies/500ng of total RNA) (III, Figure 
4S), and they were sufficient for the assay reproducibility (Stenman et al. 2001). 
Unlike PCR where the multiplex capacity is mainly limited by the formation of 
primer-dimers during the course of multiple-cycle and exponential amplification, the 
ExBP-RT assay is performed during a single cycle, thus potentially make it feasible 
for simultaneous detection of different mutations in the same reaction tube. As an 
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example, we designed a multiplex ExBP-RT assay to detect all six possible mutations 
within codon 12 of KRAS gene, including KRAS G12A, G12C, G12D, G12R, G12S 
and G12V mutations. In the same reaction of reverse transcription, there were six 
different mutation-specific primers targeting all possible KRAS mutations at codon 
12 and a common wildtype-specific ExBP probe (please see III, Table 3). 44 RNA 
samples extracted from FFPE tissues of colorectal cancer patients were used as 
templates in this example. We showed that the multiplex ExBP-RT assay detected 16 
out of 44 samples (36.4%) positive for KRAS mutations at codon 12 (III, Figure 5), 
while all tested mutation-positive and mutation-negative clinical samples contained 
comparable amounts of total KRAS RNA, which are measured with qPCR (Figure 
6S). Negative control using RNA extracted from KRAS-wildtype cell line 
(COLO205) as template, and other negative controls without template or without 
enzyme reverse transcriptase showed complete lack of amplification. There was also 
no KRAS mutation at codon 12 detected using the same multiplex ExBP-RT assay in 
another series of 87 RNA samples derived from colonoscopy biopsies of paediatric 
patients with non-malignant conditions (unpublished data), although wildtype KRAS 
was readily detected in all samples of this series. The observed mutation rate in 
archival FFPE samples from patients with colorectal cancer was slightly higher than 
reported mutation rate in a worldwide multicenter study (27.7%) using mutation 
detection assays with DNA templates (Andreyev et al. 1998), which might inspire 
further investigations to systematically compare the sensitivity of our ExBP-RT 
strategy to that of other existing technologies for mutation detection. 
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SUMMARY AND CONCLUSION 
We have been able to show that enrichment of extremely long, GC rich and/or 
repetitive sequences can be realized by converting the conventional PCR extension 
step at a constant temperature of 72°C into a dynamic extension step fluctuating 
between a basal and peak temperatures. This novel technology, named Heat Pulse 
Extension Polymerase Chain Reaction (HPE-PCR), specifically improves extension 
efficiency over such challenging sequences. As a result, it does not only enable 
amplification/enrichment of complex sequence, but also results in reduced 
amplification bias, which enables detection of extremely long, GC-rich allelic 
expansions (up to 940-GGC-repeat expansions in Fragile X syndrome) in the presence 
of a significantly shorter wildtype allele. In addition, HPE-PCR will potentially open 
many new possibilities for applications associated with multi-template PCR or 
nucleic-acid library amplification, such as in Next-Generation Sequencing 
technologies that is currently being explored by our research group. 
A convenient HPE-PCR assay has been established for detection and accurate 
sizing analysis of large expansions of CTG repeats in DM1 patients after direct 
visualization of PCR amplification products by agarose gel electrophoresis with 
conventional ethidium bromide staining. This novel DM1 assay in combination with 
touchdown PCR and fragment analysis has been adopted as a routine diagnostic assay 
at HUSLAB, Helsinki University Central Hospital.  
We were able to show that prominent cross priming during reverse transcription 
could be efficiently blocked by introduction of an Extendable Blocking Probe into the 
reverse transcription reaction (ExBP-RT). As a result, allele-specific priming during 
reverse transcription with superior selectivity can be achieved and point mutations can 
be selectively enriched, thus making it possible to detect low-abundance point 
mutation in vast excess of wildtype template by ExBP-RT. This technology is 
valuable for analysis of mutations at the RNA level, such as in analysis of expressed 
mutations in tissue or plasma, epigenetic studies to analyse allele-specific gene 
expression, miRNA variants, exosomal RNA variants or RNA editing and detection 
of mutations within the genome of RNA viruses such as HIV or Influenza viruses. 
The analytical procedure of ExBP-RT is rapid and requires only moderate 
optimization and it can be feasibly multiplexed to simultaneously detect different 
mutations in the same reaction tube, making it potentially suitable for a routine 
clinical setting. 
	   51	  
ACKNOWLEDGEMENT 
 
The study was carried out during the years 2010-2014 at the Minerva Foundation 
Institute for Medical Research and Department of Clinical Chemistry and 
Haematology. I have been financially supported by research grants from Finska 
Läkare Sällskapet, Biomedicum Helsinki Foundation, The Finnish Society of 
Sciences and Letters and University of Helsinki’s Chancellor Travel Grants. The 
support from funders is sincerely acknowledged and I am truly grateful to Professor 
Ulf-Håkan Stenman and Jakob Stenman, who have applied and arranged these 
invaluable funding opportunities for me to complete this study smoothly. 
I am grateful to all the people that I have worked with and shared my time with 
during these memorable years in Helsinki, Finland. I would especially like to 
acknowledge: 
My supervisors Jakob Stenman for the super-fast decision to “open the door” for 
me to enter this valuable doctoral course in a wonderful country and for thoughtful 
guidance delivered throughout this study, regardless of geographical distance and at 
any time I need help even in the midnight or in his holiday time; for constantly 
showing trust in my performance and encouraging me to learn how to function as an 
independent researcher; and for kind behaviour toward me as well as exceptionally 
warm support for my family in this new kingdom. Docent Arto Orpana for his 
enthusiastic instruction and continuous encouragement. I am thankful to Arto for 
endless innovative discussions that really influence my way of thinking in science and 
for his willing to share invaluable long-history expertise in development of different 
amplification technologies. 
Pre-examiners Docent Petri Auvinen and Docent Ari Hirvonen for constructive 
comments, suggestions and valuable corrections to improve my thesis in a tight 
schedule. Professor Mats Nilsson for acceptance to act as my Opponent and Professor 
Tom Böhling for kindly agreeing to be the Custos of my dissertation. 
My collaborators and co-worker Professor Dan Lindholm for teaching me basic 
Neurochemistry, giving me opportunities to join several exciting research projects and 
also for kindhearted support that enabled my family to live together during years 
studying abroad. Professor Ulf-Håkan Stenman for sharing invaluable expertise in 
different important research and strategic topics, for crucial support, for trust in me, 
and very kind consideration for me. Professor Caj Haglund for very important 
contribution and kind support to my study. Docent Vesa Olkonen for always willing 
to support my research, and ready to provide additional supervision when it was 
needed. Susanna Lintula for teaching me principles to design RT-PCR assays, and for 
kindly supporting my very first idea on development of the new amplification 
method. Lin Feng for useful discussions on various research topics, and also teaching 
	  52	  
many important daily-life basics for me, as a foreigner, to start a new life smoothly in 
Helsinki. Tuomas Tenkanen for meaningful suggestions on experiment design and 
relating my works to possible clinical usefulness at its early stage. Alise Hyrskyluoto, 
Raili Koivuniemi, for giving me an important role in exciting projects and for fruitful 
collaboration. Kien X. Dang for excellent experimental skills and productive 
cooperation. Katariina Alagrund, Maaret Ridanpää, Kristiina Aittomäki, Kristina 
Hotakainen, Emmy W. Verschuren, Kaija-Leena Kolho, Pekka Elonen, Sari Hannula 
for useful discussions and important contribution to different co-author published 
manuscripts and those under preparation. Laura Mäkelä, Anne Ahmanheimo, Eeva 
Jaaskelainen for everyday technical assistance that is fundamental for any of my 
research projects. Carita Estlander-Kortman, Cia Olsson, Tupu Nyman, Katja 
Juntunen, Anne Luoma and Tiina Himanen for readily giving kind help in response to 
any administrative issues and other matters occurring in the lab that I had no idea on 
how to deal with. I further wish to thank staffs, researchers and students at Minerva 
Foundation Institute for Medical Research: Professor Frej Fyhrquist, Professor Kid 
Törnqvist, Professor Hannele Yki-Järvinen, Professor Elina Ikonen, Docent Heikki 
Koistinen, Docent Laura Korhonen, Docent Ilkka Tikkanen, Riikka Kosonen, Jarkko 
Lakkisto, Timofey Tselykh, Tuija Mustonen, Johanna Mäkelä, Jenny Kivinen, Céline 
Bruelle,	  Annetta Luisa Redmann, Dan D. Pham, Eija Nissila, Olivier Beaslas, Marion 
Weber-Boyvat, Henriikka Kentala, Raghavendra Mysore, Hua Bian, You Zhou, 
Hoang Yen Nguyen, Selina Mäkinen, Tero Viitanen, Veronica Kalhori, Päivi 
Lakkisto, Jere Paavola, Katariina Immonen and Nidhina Haridas for all the valuable 
assistance in the lab and in my daily life, for friendly working atmosphere, and for 
sharing pleasant time in numerous occasions. 
My dear Vietnamese friends in Helsinki: Tom & Jerry’s family, Tom Em’s family, 
Mit Anh & Mit Em’s family, Meo’s family, Kem & Kun's family, Ida’s family, 
Missa’s family, Trong & Tam’s family, Trang ♥ Quang, Luong ♥ Yen, Kien ♥ Linh, 
Chinh ♥ Van, Dan, Ngoc, Dung, Loan, Thuan, Huyen, Minh, Toan and many others 
for all the support and for the warm emotion in a “big family” that is vital for me to 
keep up the good spirit during years. My friends in Vietnam: Nhim’s family, Sheva & 
Annie’s family, Le Nam, Duy, Duong, Lam, DH32’s family, 12A97’s family and 
others for special encouragement and for giving essential support to my parents and 
relatives in hardships when I have been studying far away from my home country. 
Studying in Finland has been a great honour and a wonderful experience in my life. 
Words are not enough to express my deep gratitude to this peaceful and charming 
country characterized by really cold and dark winters… but surprisingly bright 
summer, and extremely warm-hearted people that would absolutely heal any of my 
homesick feelings even in the coldest and darkest seasons of the year.  
	   53	  
I would want to express my sincere thanks to all the people who provided me with 
required knowledge, skills and passion that made possible my dream to advance my 
knowledge in this internationally well-known University of Helsinki. Professor Le 
Bach Quang and Professor Hoang Van Luong from Vietnam Military Medical 
University (VMMU), for establishing modern research facilities in VMMU and 
providing several overseas short-term training courses, which inspired me to study 
molecular medicine. Professor Nong Van Hai (Vietnam Institute of Biotechnology), 
Professor Phung Dac Cam (Vietnam National Institute of Hygiene and 
Epidemiology), Assoc Professor Nguyen Thai Son, Assoc Professor Tran Van Khoa, 
Assoc Professor Nguyen Duy Bac (VMMU), Dr. Nguyen Duc Thai, Professor Yoshi 
Nakamura (University of Tokyo), Dr. Bec Doolan and Professor Naresh Verma 
(Australian National University), for teaching me important basics and skills in 
molecular biology, and also offering me valuable opportunities to gain international 
working experience in several dynamic research groups. 
I especially want to thank my dear family: My in-laws for warmly welcoming me to 
the family and for continuous support for me since the beginning. My parents for 
devoting their own life to grow me up with an everlasting, unconditional love, and for 
being a good example for me to follow in this life about being modest, honest, 
persistent, hardworking and self-confident. My siblings and their family, my Hồ’s 
family and my Tô’s family for enthusiastic encouragement and critical support in 
hardships. 
Finally, I would like to thank Hai for sharing with me every joy and sorrow 
moments, for dedicating her heart and soul to be side-by-side with me anywhere in 
this universe and bring endless happiness to my life. It is impossible for me to focus 
and finalize any piece of this work without her invaluable role to take care of our 
family, organize everything perfectly in our home and defeated any challenges in our 
life. Dai for bringing timeless enjoyment, excellent balance between science and life, 
and the meaning to our everyday life. 
 
 
	  54	  
REFERENCES 
	  
Abravaya, K., J. J. Carrino, S. Muldoon and H. H. Lee (1995). "Detection of point mutations 
with a modified ligase chain reaction (Gap-LCR)." Nucleic Acids Res 23(4): 675-682. 
Ahmad, F. and S. A. Hashsham (2012). "Miniaturized nucleic acid amplification systems for 
rapid and point-of-care diagnostics: a review." Anal Chim Acta 733: 1-15. 
Aird, D., M. G. Ross, W. S. Chen, M. Danielsson, T. Fennell, C. Russ, D. B. Jaffe, C. 
Nusbaum and A. Gnirke (2011). "Analyzing and minimizing PCR amplification bias in 
Illumina sequencing libraries." Genome Biol 12(2): R18. 
Allingham-Hawkins, D. J., R. Babul-Hirji, D. Chitayat, J. J. Holden, K. T. Yang, C. Lee, R. 
Hudson, H. Gorwill, S. L. Nolin, A. Glicksman, E. C. Jenkins, W. T. Brown, P. N. Howard-
Peebles, C. Becchi, E. Cummings, L. Fallon, S. Seitz, S. H. Black, A. M. Vianna-Morgante, 
S. S. Costa, P. A. Otto, R. C. Mingroni-Netto, A. Murray, J. Webb, F. Vieri and et al. 
(1999). "Fragile X premutation is a significant risk factor for premature ovarian failure: the 
International Collaborative POF in Fragile X study--preliminary data." Am J Med Genet 
83(4): 322-325. 
Altshuler, D., L. D. Brooks, A. Chakravarti, F. S. Collins, M. J. Daly, P. Donnelly, R. A. Gibbs, 
J. W. Belmont, A. Boudreau, S. M. Leal, P. Hardenbol, S. Pasternak, D. A. Wheeler, T. D. 
Willis, F. L. Yu, H. M. Yang, C. Q. Zeng, Y. Gao, H. R. Hu, W. T. Hu, C. H. Li, W. Lin, S. Q. 
Liu, H. Pan, X. L. Tang, J. Wang, W. Wang, J. Yu, B. Zhang, Q. R. Zhang, H. B. Zhao, H. 
Zhao, J. Zhou, S. B. Gabriel, R. Barry, B. Blumenstiel, A. Camargo, M. Defelice, M. 
Faggart, M. Goyette, S. Gupta, J. Moore, H. Nguyen, R. C. Onofrio, M. Parkin, J. Roy, E. 
Stahl, E. Winchester, L. Ziaugra, Y. Shen, Z. J. Yao, W. Huang, X. Chu, Y. G. He, L. Jin, 
Y. F. Liu, Y. Y. Shen, W. W. Sun, H. F. Wang, Y. Wang, X. Y. Xiong, L. Xu, M. M. Y. 
Waye, S. K. W. Tsui, H. Xue, J. T. F. Wong, I. L. M. Galver, J. B. Fan, S. S. Murray, A. R. 
Oliphant, M. S. Chee, A. Montpetit, F. Chagnon, V. Ferretti, M. Leboeuf, J. F. Olivier, M. S. 
Phillips, S. Roumy, C. Sallee, A. Verner, T. J. Hudson, K. A. Frazer, D. G. Ballinger, D. R. 
Cox, D. A. Hinds, L. L. Stuve, P. Y. Kwok, D. M. Cai, D. C. Koboldt, R. D. Miller, L. 
Pawlikowska, P. Taillon-Miller, M. Xiao, L. C. Tsui, W. Mak, P. C. Sham, Y. Q. Song, P. K. 
H. Tam, Y. Nakamura, T. Kawaguchi, T. Kitamoto, T. Morizono, A. Nagashima, Y. Ohnishi, 
A. Sekine, T. Tanaka, T. Tsunoda, P. Deloukas, C. P. Bird, M. Delgado, E. T. Dermitzakis, 
R. Gwilliam, S. Hunt, J. Morrison, D. Powell, B. E. Stranger, P. Whittaker, D. R. Bentley, P. 
I. W. de Bakker, J. Barrett, B. Fry, J. Maller, S. McCarroll, N. Patterson, I. Pe'er, S. Purcell, 
D. J. Richter, P. Sabeti, R. Saxena, S. F. Schaffner, P. Varilly, L. D. Stein, L. Krishnan, A. 
V. Smith, G. A. Thorisson, P. E. Chen, D. J. Cutler, C. S. Kashuk, S. Lin, G. R. Abecasis, 
W. H. Guan, H. M. Munro, Z. H. S. Qin, D. J. Thomas, G. McVean, L. Bottolo, S. 
Eyheramendy, C. Freeman, J. Marchini, S. Myers, C. Spencer, M. Stephens, L. R. 
Cardon, G. Clarke, D. M. Evans, A. P. Morris, B. S. Weir, J. C. Mullikin, S. T. Sherry, M. 
Feolo, H. C. Zhang, I. Matsuda, Y. Fukushima, D. R. Macer, E. Suda, C. N. Rotimi, C. A. 
Adebamowo, I. Ajayi, T. Aniagwu, P. A. Marshall, C. Nkwodimmah, C. D. M. Royal, M. F. 
Leppert, M. Dixon, A. Peiffer, R. Z. Qiu, A. Kent, K. Kato, N. Niikawa, I. F. Adewole, B. M. 
Knoppers, M. W. Foster, E. W. Clayton, D. Muzny, L. Nazareth, E. Sodergren, G. M. 
Weinstock, I. Yakub, B. W. Birren, R. K. Wilson, L. L. Fulton, J. Rogers, J. Burton, N. P. 
Carter, C. M. Clee, M. Griffiths, M. C. Jones, K. McLay, R. W. Plumb, M. T. Ross, S. K. 
Sims, D. L. Willey, Z. Chen, H. Han, L. Kang, M. Godbout, J. C. Wallenburg, P. L. 
Archeveque, G. Bellemare, K. Saeki, H. G. Wang, D. C. An, H. B. Fu, Q. Li, Z. Wang, R. 
W. Wang, A. L. Holden, J. E. McEwen, C. R. Bird, M. S. Guyer, P. J. Nailer, V. O. Wang, 
J. L. Peterson, M. Shi, J. Spiegel, L. M. Sung, J. Witonsky, L. F. Zacharia, K. Kennedy, R. 
Jamieson, J. Stewart and C. Int HapMap (2005). "A haplotype map of the human 
genome." Nature 437(7063): 1299-1320. 
Alves, A. M. and F. J. Carr (1988). "Dot blot detection of point mutations with adjacently 
hybridising synthetic oligonucleotide probes." Nucleic Acids Res 16(17): 8723. 
Andreyev, H. J., A. R. Norman, D. Cunningham, J. R. Oates and P. A. Clarke (1998). "Kirsten 
ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study." J Natl 
Cancer Inst 90(9): 675-684. 
	   55	  
Ayyadevara, S., J. J. Thaden and R. J. Shmookler Reis (2000). "Discrimination of primer 3'-
nucleotide mismatch by taq DNA polymerase during polymerase chain reaction." Anal 
Biochem 284(1): 11-18. 
Bachmann, B., W. Luke and G. Hunsmann (1990). "Improvement of PCR amplified DNA 
sequencing with the aid of detergents." Nucleic Acids Research 18(5): 1309-1309. 
Bachmann, H. S., W. Siffert and U. H. Frey (2003). "Successful amplification of extremely 
GC-rich promoter regions using a novel 'slowdown PCR' technique." Pharmacogenetics 
13(12): 759-766. 
Barcellos, L. F., W. Klitz, L. L. Field, R. Tobias, A. M. Bowcock, R. Wilson, M. P. Nelson, J. 
Nagatomi and G. Thomson (1997). "Association mapping of disease loci, by use of a 
pooled DNA genomic screen." Am J Hum Genet 61(3): 734-747. 
Barnes, W. M. (1994). "PCR amplification of up to 35-kb DNA with high fidelity and high yield 
from lambda bacteriophage templates." Proc Natl Acad Sci U S A 91(6): 2216-2220. 
Baskaran, N., R. P. Kandpal, A. K. Bhargava, M. W. Glynn, A. Bale and S. M. Weissman 
(1996). "Uniform amplification of a mixture of deoxyribonucleic acids with varying GC 
content." Genome Res 6(7): 633-638. 
Beau-Faller, M., M. Legrain, A. C. Voegeli, E. Guerin, T. Lavaux, A. M. Ruppert, A. Neuville, 
G. Massard, J. M. Wihlm, E. Quoix, P. Oudet and M. P. Gaub (2009). "Detection of K-Ras 
mutations in tumour samples of patients with non-small cell lung cancer using PNA-
mediated PCR clamping." British Journal of Cancer 100(6): 985-992. 
Bos, J. L. (1989). "ras oncogenes in human cancer: a review." Cancer Res 49(17): 4682-
4689. 
Bottema, C. D. and S. S. Sommer (1993). "PCR amplification of specific alleles: rapid 
detection of known mutations and polymorphisms." Mutat Res 288(1): 93-102. 
Bouche, O., G. D. Beretta, P. G. Alfonso and M. Geissler (2010). "The role of anti-epidermal 
growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic 
colorectal cancer." Cancer Treat Rev 36 Suppl 1: S1-10. 
Bowater, R. P. and R. D. Wells (2001). "The intrinsically unstable life of DNA triplet repeats 
associated with human hereditary disorders." Prog Nucleic Acid Res Mol Biol 66: 159-202. 
Brink, M., A. F. de Goeij, M. P. Weijenberg, G. M. Roemen, M. H. Lentjes, M. M. Pachen, K. 
M. Smits, A. P. de Bruine, R. A. Goldbohm and P. A. van den Brandt (2003). "K-ras 
oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study." 
Carcinogenesis 24(4): 703-710. 
Brown, W. T., S. Nolin, G. Houck, Jr., X. Ding, A. Glicksman, S. Y. Li, S. Stark-Houck, P. 
Brophy, C. Duncan, C. Dobkin and E. Jenkins (1996). "Prenatal diagnosis and carrier 
screening for fragile X by PCR." Am J Med Genet 64(1): 191-195. 
Center, M. M., A. Jemal and E. Ward (2009). "International trends in colorectal cancer 
incidence rates." Cancer Epidemiol Biomarkers Prev 18(6): 1688-1694. 
Cha, R. S., H. Zarbl, P. Keohavong and W. G. Thilly (1992). "Mismatch amplification mutation 
assay (MAMA): application to the c-H-ras gene." PCR Methods Appl 2(1): 14-20. 
Chakrabarti, R. and C. E. Schutt (2001). "The enhancement of PCR amplification by low 
molecular weight amides." Nucleic Acids Res 29(11): 2377-2381. 
Chan Yoke, F., L. Tan Kim, C. Wong Yean, C. Wee Yong, F. Yap Sook and A. Tan Jin Ai 
Mary (2001). "The use of the amplification refractory mutation system (arms) in the 
detection of rare beta-thalassemia mutations in the Malays and Chinese in Malaysia." 
Southeast Asian J Trop Med Public Health 32(4): 872-879. 
Chehab, F. F. and Y. W. Kan (1989). "Detection of specific DNA sequences by fluorescence 
amplification: a color complementation assay." Proc Natl Acad Sci U S A 86(23): 9178-
9182. 
Chen, X., S. V. Mariappan, P. Catasti, R. Ratliff, R. K. Moyzis, A. Laayoun, S. S. Smith, E. M. 
Bradbury and G. Gupta (1995). "Hairpins are formed by the single DNA strands of the 
fragile X triplet repeats: structure and biological implications." Proc Natl Acad Sci U S A 
92(11): 5199-5203. 
Chen, X. and P. F. Sullivan (2003). "Single nucleotide polymorphism genotyping: 
biochemistry, protocol, cost and throughput." Pharmacogenomics Journal 3(2): 77-96. 
Cheng, S., J. M. Barcelo and R. G. Korneluk (1996). "Characterization of large CTG repeat 
expansions in myotonic dystrophy alleles using PCR." Human Mutation 7(4): 304-310. 
	  56	  
Cheng, S., C. Fockler, W. M. Barnes and R. Higuchi (1994). "Effective Amplification of Long 
Targets from Cloned Inserts and Human Genomic DNA." Proceedings of the National 
Academy of Sciences of the United States of America 91(12): 5695-5699. 
Chou, Q. (1992). "Minimizing deletion mutagenesis artifact during Taq DNA polymerase PCR 
by E. coli SSB." Nucleic Acids Res 20(16): 4371. 
Clayton, S. J., F. M. Scott, J. Walker, K. Callaghan, K. Haque, T. Liloglou, G. Xinarianos, S. 
Shawcross, P. Ceuppens, J. K. Field and J. C. Fox (2000). "K-ras point mutation detection 
in lung cancer: comparison of two approaches to somatic mutation detection using ARMS 
allele-specific amplification." Clin Chem 46(12): 1929-1938. 
Creighton, S., M. M. Huang, H. Cai, N. Arnheim and M. F. Goodman (1992). "Base Mispair 
Extension Kinetics - Binding of Avian-Myeloblastosis Reverse-Transcriptase to Matched 
and Mismatched Base Pair Termini." Journal of Biological Chemistry 267(4): 2633-2639. 
Dahlen, P., J. Carlson, L. Liukkonen, H. Lilja, H. Siitari, P. Hurskainen, A. Iita, J. O. Jeppsson 
and T. Lovgren (1993). "Europium-labeled oligonucleotides to detect point mutations: 
application to PIZ alpha 1-antitrypsin deficiency." Clin Chem 39(8): 1626-1631. 
Darlow, J. M. and D. R. Leach (1998). "Secondary structures in d(CGG) and d(CCG) repeat 
tracts." J Mol Biol 275(1): 3-16. 
Didelot, A., D. Le Corre, A. Luscan, A. Cazes, K. Pallier, J. F. Emile, P. Laurent-Puig and H. 
Blons (2012). "Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR 
mutation detection in clinical formalin fixed paraffin embedded samples." Exp Mol Pathol 
92(3): 275-280. 
Dierick, H., M. Stul, W. De Kelver, P. Marynen and J. J. Cassiman (1993). "Incorporation of 
dITP or 7-deaza dGTP during PCR improves sequencing of the product." Nucleic Acids 
Res 21(18): 4427-4428. 
Do, H., M. Krypuy, P. L. Mitchell, S. B. Fox and A. Dobrovic (2008). "High resolution melting 
analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed 
paraffin embedded biopsies." BMC Cancer 8: 142. 
Don, R. H., P. T. Cox, B. J. Wainwright, K. Baker and J. S. Mattick (1991). "'Touchdown' PCR 
to circumvent spurious priming during gene amplification." Nucleic Acids Res 19(14): 
4008. 
Dutton, C. and S. S. Sommer (1991). "Simultaneous detection of multiple single-base alleles 
at a polymorphic site." Biotechniques 11(6): 700-702. 
Farell, E. M. and G. Alexandre (2012). "Bovine serum albumin further enhances the effects of 
organic solvents on increased yield of polymerase chain reaction of GC-rich templates." 
BMC Res Notes 5: 257. 
Farr, C. J., R. K. Saiki, H. A. Erlich, F. McCormick and C. J. Marshall (1988). "Analysis of 
RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and 
oligonucleotide probes." Proc Natl Acad Sci U S A 85(5): 1629-1633. 
Ferlay, J., P. Autier, M. Boniol, M. Heanue, M. Colombet and P. Boyle (2007). "Estimates of 
the cancer incidence and mortality in Europe in 2006." Ann Oncol 18(3): 581-592. 
Fernandez-Carvajal, I., B. Lopez Posadas, R. Pan, C. Raske, P. J. Hagerman and F. 
Tassone (2009). "Expansion of an FMR1 grey-zone allele to a full mutation in two 
generations." J Mol Diagn 11(4): 306-310. 
Fernandez-Rachubinski, F., B. Eng, W. W. Murray, M. A. Blajchman and R. A. Rachubinski 
(1990). "Incorporation of 7-deaza dGTP during the amplification step in the polymerase 
chain reaction procedure improves subsequent DNA sequencing." DNA Seq 1(2): 137-
140. 
Filipovic-Sadic, S., S. Sah, L. Chen, J. Krosting, E. Sekinger, W. Zhang, P. J. Hagerman, T. 
T. Stenzel, A. G. Hadd, G. J. Latham and F. Tassone (2010). "A novel FMR1 PCR method 
for the routine detection of low abundance expanded alleles and full mutations in fragile X 
syndrome." Clin Chem 56(3): 399-408. 
Flys, T., D. V. Nissley, C. W. Claasen, D. Jones, C. Shi, L. A. Guay, P. Musoke, F. Mmiro, J. 
N. Strathern, J. B. Jackson, J. R. Eshleman and S. H. Eshleman (2005). "Sensitive drug-
resistance assays reveal long-term persistence of HIV-1 variants with the K103N 
nevirapine (NVP) resistance mutation in some women and infants after the administration 
of single-dose NVP: HIVNET 012." J Infect Dis 192(1): 24-29. 
Fox, J. C., J. England, P. White, G. Ellison, K. Callaghan, N. R. Charlesworth, J. Hehir, T. L. 
McCarthy, J. Smith-Ravin, I. C. Talbot, D. Snary, J. M. Northover, C. R. Newton and S. 
	   57	  
Little (1998). "The detection of K-ras mutations in colorectal cancer using the amplification-
refractory mutation system." Br J Cancer 77(8): 1267-1274. 
Frayling, I. M. (2002). "Methods of molecular analysis: mutation detection in solid tumours." 
Mol Pathol 55(2): 73-79. 
Frey, U. H., H. S. Bachmann, J. Peters and W. Siffert (2008). "PCR-amplification of GC-rich 
regions: 'slowdown PCR'." Nat Protoc 3(8): 1312-1317. 
Gao, Y., L. K. Wolf and R. M. Georgiadis (2006). "Secondary structure effects on DNA 
hybridization kinetics: a solution versus surface comparison." Nucleic Acids Res 34(11): 
3370-3377. 
Gennarelli, M., M. Pavoni, P. Amicucci, G. Novelli and B. Dallapiccola (1998). "A single 
polymerase chain reaction-based protocol for detecting normal and expanded alleles in 
myotonic dystrophy." Diagn Mol Pathol 7(3): 135-137. 
Gibbs, R. A., P. N. Nguyen and C. T. Caskey (1989). "Detection of single DNA base 
differences by competitive oligonucleotide priming." Nucleic Acids Res 17(7): 2437-2448. 
Giffard, P. M. (2001). "Comparison of Competitively Primed and Conventional Allele-Specific 
Nucleic Acid Amplification." Analytical Biochemistry 292(2): 207-215. 
Haddad, L. A., R. C. Mingroni-Netto, A. M. Vianna-Morgante and S. D. J. Pena (1996). "A 
PCR-based test suitable for screening for fragile X syndrome among mentally retarded 
males." Human Genetics 97(6): 808-812. 
Hagerman, R. J., M. Leehey, W. Heinrichs, F. Tassone, R. Wilson, J. Hills, J. Grigsby, B. 
Gage and P. J. Hagerman (2001). "Intention tremor, parkinsonism, and generalized brain 
atrophy in male carriers of fragile X." Neurology 57(1): 127-130. 
Hamdan, H., J. A. Tynan, R. A. Fenwick and J. A. Leon (1997). "Automated Detection of 
Trinucleotide Repeats in Fragile X Syndrome." Mol Diagn 2(4): 259-269. 
Harley, H. G., S. A. Rundle, W. Reardon, J. Myring, S. Crow, J. D. Brook, P. S. Harper and D. 
J. Shaw (1992). "Unstable DNA sequence in myotonic dystrophy." Lancet 339(8802): 
1125-1128. 
Hecimovic, S., J. Vlasic, L. Barisic, D. Markovic, V. Culic and K. Pavelic (2001). "A simple and 
rapid analysis of triplet repeat diseases by expand long PCR." Clinical Chemistry and 
Laboratory Medicine 39(12): 1259-1262. 
Hecker, K. H. and K. H. Roux (1996). "High and low annealing temperatures increase both 
specificity and yield in touchdown and stepdown PCR." Biotechniques 20(3): 478-485. 
Henke, W., K. Herdel, K. Jung, D. Schnorr and S. A. Loening (1997). "Betaine improves the 
PCR amplification of GC-rich DNA sequences." Nucleic Acids Res 25(19): 3957-3958. 
Hoda, D., G. R. Simon and C. R. Garrett (2008). "Targeting colorectal cancer with anti-
epidermal growth factor receptor antibodies: focus on panitumumab." Ther Clin Risk 
Manag 4(6): 1221-1227. 
Horiuchi, H., M. Osawa, R. Furutani, M. Morita, W. Tian, Y. Awatsu, H. Shimazaki and K. 
Umetsu (2005). "Polymerase chain reaction-based analysis using deaminated DNA of 
dodecamer expansions in CSTB, associated with Unverricht-Lundborg myoclonus 
epilepsy." Genet Test 9(4): 328-333. 
Houdayer, C., A. Lemonnier, M. Gerard, C. Chauve, M. Tredano, T. B. de Villemeur, P. 
Aymard, J. P. Bonnefont and D. Feldmann (1999). "Improved fluorescent PCR-based 
assay for sizing CGG repeats at the FRAXA locus." Clinical Chemistry and Laboratory 
Medicine 37(4): 397-401. 
Hube, F., P. Reverdiau, S. Iochmann and Y. Gruel (2005). "Improved PCR method for 
amplification of GC-rich DNA sequences." Mol Biotechnol 31(1): 81-84. 
Hunter, A., C. Tsilfidis, G. Mettler, P. Jacob, M. Mahadevan, L. Surh and R. Korneluk (1992). 
"The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic 
dystrophy." J Med Genet 29(11): 774-779. 
Imbert, G., C. Kretz, K. Johnson and J. L. Mandel (1993). "Origin of the expansion mutation in 
myotonic dystrophy." Nat Genet 4(1): 72-76. 
Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun (2009). "Cancer statistics, 2009." 
CA Cancer J Clin 59(4): 225-249. 
Kanagawa, T. (2003). "Bias and artifacts in multitemplate polymerase chain reactions (PCR)." 
Journal of Bioscience and Bioengineering 96(4): 317-323. 
Karapetis, C. S., S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. 
J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, T. J. Price, L. Shepherd, H. J. Au, C. 
	  58	  
Langer, M. J. Moore and J. R. Zalcberg (2008). "K-ras mutations and benefit from 
cetuximab in advanced colorectal cancer." N Engl J Med 359(17): 1757-1765. 
Kim, S. and A. Misra (2007). "SNP genotyping: Technologies and biomedical applications." 
Annual Review of Biomedical Engineering 9: 289-320. 
Kopetz, S., G. J. Chang, M. J. Overman, C. Eng, D. J. Sargent, D. W. Larson, A. Grothey, J. 
N. Vauthey, D. M. Nagorney and R. R. McWilliams (2009). "Improved survival in 
metastatic colorectal cancer is associated with adoption of hepatic resection and improved 
chemotherapy." J Clin Oncol 27(22): 3677-3683. 
Kropp, G. L., S. Fucharoen and S. H. Embury (1991). "Asymmetrically primed selective 
amplification/temperature shift fluorescence polymerase chain reaction to detect the 
hemoglobin Constant Spring mutation." Blood 78(1): 26-29. 
Krypuy, M., G. M. Newnham, D. M. Thomas, M. Conron and A. Dobrovic (2006). "High 
resolution melting analysis for the rapid and sensitive detection of mutations in clinical 
samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer." BMC Cancer 6: 
295. 
Kwok, S., D. E. Kellogg, N. McKinney, D. Spasic, L. Goda, C. Levenson and J. J. Sninsky 
(1990). "Effects of primer-template mismatches on the polymerase chain reaction: human 
immunodeficiency virus type 1 model studies." Nucleic Acids Res 18(4): 999-1005. 
Landegren, U., R. Kaiser, J. Sanders and L. Hood (1988). "A ligase-mediated gene detection 
technique." Science 241(4869): 1077-1080. 
Larsson, C., I. Grundberg, O. Soderberg and M. Nilsson (2010). "In situ detection and 
genotyping of individual mRNA molecules." Nat Methods 7(5): 395-397. 
Latorra, D., K. Campbell, A. Wolter and J. M. Hurley (2003). "Enhanced allele-specific PCR 
discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers." Hum Mutat 
22(1): 79-85. 
Lee, C. H., H. Mizusawa and T. Kakefuda (1981). "Unwinding of Double-Stranded DNA Helix 
by Dehydration." Proceedings of the National Academy of Sciences of the United States of 
America-Biological Sciences 78(5): 2838-2842. 
Li, H., X. Cui and N. Arnheim (1990). "Direct electrophoretic detection of the allelic state of 
single DNA molecules in human sperm by using the polymerase chain reaction." Proc Natl 
Acad Sci U S A 87(12): 4580-4584. 
Lievre, A., J. B. Bachet, D. Le Corre, V. Boige, B. Landi, J. F. Emile, J. F. Cote, G. Tomasic, 
C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca and P. Laurent-Puig (2006). "KRAS 
mutation status is predictive of response to cetuximab therapy in colorectal cancer." 
Cancer Res 66(8): 3992-3995. 
Lindroos, K., U. Liljedahl, M. Raitio and A. C. Syvänen (2001). "Minisequencing on 
oligonucleotide microarrays: comparison of immobilisation chemistries." Nucleic Acids Res 
29(13): E69-69. 
Liu, Q. and S. S. Sommer (2004). "PAP: detection of ultra rare mutations depends on P* 
oligonucleotides: "sleeping beauties" awakened by the kiss of pyrophosphorolysis." Hum 
Mutat 23(5): 426-436. 
Lizardi, P. M., X. H. Huang, Z. R. Zhu, P. Bray-Ward, D. C. Thomas and D. C. Ward (1998). 
"Mutation detection and single-molecule counting using isothermal rolling-circle 
amplification." Nature Genetics 19(3): 225-232. 
Maddalena, A., C. S. Richards, M. J. McGinniss, A. Brothman, R. J. Desnick, R. E. Grier, B. 
Hirsch, P. Jacky, G. A. McDowell, B. Popovich, M. Watson and D. J. Wolff (2001). 
"Technical standards and guidelines for fragile X: the first of a series of disease-specific 
supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the 
American College of Medical Genetics. Quality Assurance Subcommittee of the 
Laboratory Practice Committee." Genet Med 3(3): 200-205. 
Mahadevan, M., C. Tsilfidis, L. Sabourin, G. Shutler, C. Amemiya, G. Jansen, C. Neville, M. 
Narang, J. Barcelo, K. O'Hoy and et al. (1992). "Myotonic dystrophy mutation: an unstable 
CTG repeat in the 3' untranslated region of the gene." Science 255(5049): 1253-1255. 
Mamedov, T. G., E. Pienaar, S. E. Whitney, J. R. TerMaat, G. Carvill, R. Goliath, A. 
Subramanian and H. J. Viljoen (2008). "A fundamental study of the PCR amplification of 
GC-rich DNA templates." Comput Biol Chem 32(6): 452-457. 
Markham, N. R. and M. Zuker (2005). "DINAMelt web server for nucleic acid melting 
prediction." Nucleic Acids Res 33(Web Server issue): W577-581. 
	   59	  
Matyas, G., C. Giunta, B. Steinmann, J. P. Hossle and R. Hellwig (2002). "Quantification of 
single nucleotide polymorphisms: A novel method that combines primer extension assay 
and capillary electrophoresis." Human Mutation 19(1): 58-68. 
McConlogue, L., M. A. Brow and M. A. Innis (1988). "Structure-independent DNA 
amplification by PCR using 7-deaza-2'-deoxyguanosine." Nucleic Acids Res 16(20): 9869. 
McDowell, D. G., N. A. Burns and H. C. Parkes (1998). "Localised sequence regions 
possessing high melting temperatures prevent the amplification of a DNA mimic in 
competitive PCR." Nucleic Acids Res 26(14): 3340-3347. 
McKinzie, P. B. and B. L. Parsons (2002). "Detection of rare K-ras codon 12 mutations using 
allele-specific competitive blocker PCR." Mutat Res 517(1-2): 209-220. 
Melchior, W. B., Jr. and P. H. Von Hippel (1973). "Alteration of the relative stability of dA-dT 
and dG-dC base pairs in DNA." Proc Natl Acad Sci U S A 70(2): 298-302. 
Mendelman, L. V., J. Petruska and M. F. Goodman (1990). "Base mispair extension kinetics. 
Comparison of DNA polymerase alpha and reverse transcriptase." J Biol Chem 265(4): 
2338-2346. 
Mendelsohn, J. and J. Baselga (2003). "Status of epidermal growth factor receptor 
antagonists in the biology and treatment of cancer." J Clin Oncol 21(14): 2787-2799. 
Milbury, C. A., J. Li and G. M. Makrigiorgos (2009). "PCR-Based Methods for the Enrichment 
of Minority Alleles and Mutations." Clinical Chemistry 55(4): 632-640. 
Milbury, C. A., J. Li and G. M. Makrigiorgos (2011). "Ice-COLD-PCR enables rapid 
amplification and robust enrichment for low-abundance unknown DNA mutations." Nucleic 
Acids Res 39(1): e2. 
Mirkin, S. M. (2006). "DNA structures, repeat expansions and human hereditary disorders." 
Curr Opin Struct Biol 16(3): 351-358. 
Mirkin, S. M. (2007). "Expandable DNA repeats and human disease." Nature 447(7147): 932-
940. 
Morlan, J., J. Baker, D. Sinicropi and I. Schrijver (2009). "Mutation Detection by Real-Time 
PCR: A Simple, Robust and Highly Selective Method." PLoS ONE 4(2): e4584. 
Mullis, K., F. Faloona, S. Scharf, R. Saiki, G. Horn and H. Erlich (1986). "Specific enzymatic 
amplification of DNA in vitro: the polymerase chain reaction." Cold Spring Harb Symp 
Quant Biol 51 Pt 1: 263-273. 
Murphy, K. M., T. Geiger, M. J. Hafez, J. R. Eshleman, C. A. Griffin and K. D. Berg (2003). "A 
single nucleotide primer extension assay to detect the APC I1307K gene variant." J Mol 
Diagn 5(4): 222-226. 
Murray, J., P. Sonnenberg, S. Shearer and P. Godfrey-Faussett (2000). "Drug-resistant 
pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence 
of HIV infection." S Afr Med J 90(4): 381-386. 
Musso, M., R. Bocciardi, S. Parodi, R. Ravazzolo and I. Ceccherini (2006). "Betaine, dimethyl 
sulfoxide, and 7-deaza-dGTP, a powerful mixture for amplification of GC-rich DNA 
sequences." J Mol Diagn 8(5): 544-550. 
Nash, D., L. G. Paleg and J. T. Wiskich (1982). "Effect of Proline, Betaine and Some Other 
Solutes on the Heat-Stability of Mitochondrial-Enzymes." Australian Journal of Plant 
Physiology 9(1): 47-57. 
NCCN (2009). "NCCN Clinical practice guidelines in Oncology." 
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. 
Newton, C. R., A. Graham, L. E. Heptinstall, S. J. Powell, C. Summers, N. Kalsheker, J. C. 
Smith and A. F. Markham (1989). "Analysis of any point mutation in DNA. The 
amplification refractory mutation system (ARMS)." Nucleic Acids Res 17(7): 2503-2516. 
Newton, C. R., C. Summers, L. E. Heptinstall, J. R. Lynch, R. S. Finniear, D. Ogilvie, J. C. 
Smith and A. F. Markham (1991). "Genetic analysis in cystic fibrosis using the 
amplification refractory mutation system (ARMS): the J3.11 MspI polymorphism." J Med 
Genet 28(4): 248-251. 
Nikiforov, T. T., R. B. Rendle, P. Goelet, Y. H. Rogers, M. L. Kotewicz, S. Anderson, G. L. 
Trainor and M. R. Knapp (1994). "Genetic Bit Analysis: a solid phase method for typing 
single nucleotide polymorphisms." Nucleic Acids Res 22(20): 4167-4175. 
Nilsson, M., G. Barbany, D. O. Antson, K. Gertow and U. Landegren (2000). "Enhanced 
detection and distinction of RNA by enzymatic probe ligation." Nat Biotechnol 18(7): 791-
793. 
	  60	  
Nolin, S. L., W. T. Brown, A. Glicksman, G. E. Houck, Jr., A. D. Gargano, A. Sullivan, V. 
Biancalana, K. Brondum-Nielsen, H. Hjalgrim, E. Holinski-Feder, F. Kooy, J. Longshore, J. 
Macpherson, J. L. Mandel, G. Matthijs, F. Rousseau, P. Steinbach, M. L. Väisänen, H. von 
Koskull and S. L. Sherman (2003). "Expansion of the fragile X CGG repeat in females with 
premutation or intermediate alleles." Am J Hum Genet 72(2): 454-464. 
Nollau, P. and C. Wagener (1997). "Methods for detection of point mutations: performance 
and quality assessment. IFCC Scientific Division, Committee on Molecular Biology 
Techniques." Clin Chem 43(7): 1114-1128. 
Normanno, N., S. Tejpar, F. Morgillo, A. De Luca, E. Van Cutsem and F. Ciardiello (2009). 
"Implications for KRAS status and EGFR-targeted therapies in metastatic CRC." Nat Rev 
Clin Oncol 6(9): 519-527. 
O'Connell, C. D., D. H. Atha, J. P. Jakupciak, J. A. Amos and K. Richie (2002). 
"Standardization of PCR amplification for fragile X trinucleotide repeat measurements." 
Clin Genet 61(1): 13-20. 
Oberle, I., F. Rousseau, D. Heitz, C. Kretz, D. Devys, A. Hanauer, J. Boue, M. F. Bertheas 
and J. L. Mandel (1991). "Instability of a 550-base pair DNA segment and abnormal 
methylation in fragile X syndrome." Science 252(5010): 1097-1102. 
Ogino, S., T. Kawasaki, G. J. Kirkner, Y. Suemoto, J. A. Meyerhardt and C. S. Fuchs (2007). 
"Molecular correlates with MGMT promoter methylation and silencing support CpG island 
methylator phenotype-low (CIMP-low) in colorectal cancer." Gut 56(11): 1564-1571. 
Okayama, H., D. T. Curiel, M. L. Brantly, M. D. Holmes and R. G. Crystal (1989). "Rapid, 
nonradioactive detection of mutations in the human genome by allele-specific 
amplification." J Lab Clin Med 114(2): 105-113. 
Orou, A., B. Fechner, G. Utermann and H. J. Menzel (1995). "Allele-specific competitive 
blocker PCR: a one-step method with applicability to pool screening." Hum Mutat 6(2): 
163-169. 
Ouldridge, T. E., P. Sulc, F. Romano, J. P. Doye and A. A. Louis (2013). "DNA hybridization 
kinetics: zippering, internal displacement and sequence dependence." Nucleic Acids Res 
41(19): 8886-8895. 
Parkin, D. M., F. Bray, J. Ferlay and P. Pisani (2005). "Global cancer statistics, 2002." CA 
Cancer J Clin 55(2): 74-108. 
Parsons, B. L. and R. H. Heflich (1997). "Genotypic selection methods for the direct analysis 
of point mutations." Mutat Res 387(2): 97-121. 
Parsons, B. L., P. B. McKinzie and R. H. Heflich (2005). "Allele-specific competitive blocker-
PCR detection of rare base substitution." Methods Mol Biol 291: 235-245. 
Pastinen, T., J. Partanen and A. C. Syvänen (1996). "Multiplex, fluorescent, solid-phase 
minisequencing for efficient screening of DNA sequence variation." Clin Chem 42(9): 
1391-1397. 
Patel, D. K. (2008). "Clinical use of anti-epidermal growth factor receptor monoclonal 
antibodies in metastatic colorectal cancer." Pharmacotherapy 28(11 Pt 2): 31S-41S. 
Pearson, C. E. and R. R. Sinden (1996). "Alternative structures in duplex DNA formed within 
the trinucleotide repeats of the myotonic dystrophy and fragile X loci." Biochemistry 
35(15): 5041-5053. 
Polz, M. F. and C. M. Cavanaugh (1998). "Bias in template-to-product ratios in multitemplate 
PCR." Applied and Environmental Microbiology 64(10): 3724-3730. 
Pomp, D. and J. F. Medrano (1991). "Organic-Solvents as Facilitators of Polymerase Chain-
Reaction." Biotechniques 10(1): 58-59. 
Pozzo, C., C. Barone and N. E. Kemeny (2008). "Advances in neoadjuvant therapy for 
colorectal cancer with liver metastases." Cancer Treat Rev 34(4): 293-301. 
Puthillath, A., A. Patel and M. G. Fakih (2009). "Targeted therapies in the management of 
colorectal carcinoma: role of bevacizumab." Onco Targets Ther 2: 1-15. 
Radvansky, J. and L. Kadasi (2010). "The expanding world of myotonic dystrophies: how can 
they be detected?" Genet Test Mol Biomarkers 14(6): 733-741. 
Rees, W. A., T. D. Yager, J. Korte and P. H. von Hippel (1993). "Betaine can eliminate the 
base pair composition dependence of DNA melting." Biochemistry 32(1): 137-144. 
Rowley, C. F., C. L. Boutwell, E. J. Lee, I. J. MacLeod, H. J. Ribaudo, M. Essex and S. 
Lockman (2010). "Ultrasensitive detection of minor drug-resistant variants for HIV after 
nevirapine exposure using allele-specific PCR: clinical significance." AIDS Res Hum 
Retroviruses 26(3): 293-300. 
	   61	  
Rubin, M. A. (2002). "Tech.Sight. Understanding disease cell by cell." Science 296(5571): 
1329-1330. 
Sahdev, S., S. Saini, P. Tiwari, S. Saxena and K. Singh Saini (2007). "Amplification of GC-
rich genes by following a combination strategy of primer design, enhancers and modified 
PCR cycle conditions." Mol Cell Probes 21(4): 303-307. 
Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis and H. 
A. Erlich (1988). "Primer-directed enzymatic amplification of DNA with a thermostable 
DNA polymerase." Science 239(4839): 487-491. 
Saiki, R. K., S. Scharf, F. Faloona, K. B. Mullis, G. T. Horn, H. A. Erlich and N. Arnheim 
(1985). "Enzymatic amplification of beta-globin genomic sequences and restriction site 
analysis for diagnosis of sickle cell anemia." Science 230(4732): 1350-1354. 
Saiki, R. K., P. S. Walsh, C. H. Levenson and H. A. Erlich (1989). "Genetic analysis of 
amplified DNA with immobilized sequence-specific oligonucleotide probes." Proc Natl 
Acad Sci U S A 86(16): 6230-6234. 
Saluto, A., A. Brussino, F. Tassone, C. Arduino, C. Cagnoli, P. Pappi, P. Hagerman, N. 
Migone and A. Brusco (2005). "An enhanced polymerase chain reaction assay to detect 
pre- and full mutation alleles of the fragile X mental retardation 1 gene." J Mol Diagn 7(5): 
605-612. 
Samowitz, W. S., K. Curtin, D. Schaffer, M. Robertson, M. Leppert and M. L. Slattery (2000). 
"Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a 
population-based study." Cancer Epidemiol Biomarkers Prev 9(11): 1193-1197. 
SantaLucia, J., Jr. (1998). "A unified view of polymer, dumbbell, and oligonucleotide DNA 
nearest-neighbor thermodynamics." Proc Natl Acad Sci U S A 95(4): 1460-1465. 
Sapio, M. R. (2006). "Detection of BRAF mutation in thyroid papillary carcinomas by mutant 
allele-specific PCR amplification (MASA)." European Journal of Endocrinology 154(2): 
341-348. 
Schuchard, M., G. Sarkar, T. Ruesink and T. C. Spelsberg (1993). "Two-step "hot" PCR 
amplification of GC-rich avian c-myc sequences." Biotechniques 14(3): 390-394. 
Seto, D., J. Seto, P. Deshpande and L. Hood (1995). "DMSO resolves certain compressions 
and signal dropouts in fluorescent dye labeled primer-based DNA sequencing reactions." 
DNA Seq 5(3): 131-140. 
Seyama, T., T. Ito, T. Hayashi, T. Mizuno, N. Nakamura and M. Akiyama (1992). "A novel 
blocker-PCR method for detection of rare mutant alleles in the presence of an excess 
amount of normal DNA." Nucleic Acids Res 20(10): 2493-2496. 
Shi, C., S. H. Eshleman, D. Jones, N. Fukushima, L. Hua, A. R. Parker, C. J. Yeo, R. H. 
Hruban, M. G. Goggins and J. R. Eshleman (2004). "LigAmp for sensitive detection of 
single-nucleotide differences." Nat Methods 1(2): 141-147. 
Shi, M. M. (2001). "Enabling large-scale pharmacogenetic studies by high-throughput 
mutation detection and genotyping technologies." Clin Chem 47(2): 164-172. 
Simi, L., N. Pratesi, M. Vignoli, R. Sestini, F. Cianchi, R. Valanzano, S. Nobili, E. Mini, M. 
Pazzagli and C. Orlando (2008). "High-resolution melting analysis for rapid detection of 
KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer." Am J Clin Pathol 130(2): 
247-253. 
Skrzypczak-Zielinska, M., A. Sulek-Piatkowska, M. Mierzejewski and U. G. Froster (2009). 
"New analysis method of myotonic dystrophy 1 based on quantitative fluorescent 
polymerase chain reaction." Genet Test Mol Biomarkers 13(5): 651-655. 
Smith, G. D., L. Zhou, L. R. Rowe, E. A. Jarboe, B. T. Collins, J. S. Bentz, C. T. Wittwer and 
B. E. Chadwick (2011). "Allele-specific PCR with competitive probe blocking for sensitive 
and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens." Acta 
Cytol 55(6): 576-583. 
Sokolov, B. P. (1990). "Primer extension technique for the detection of single nucleotide in 
genomic DNA." Nucleic Acids Res 18(12): 3671. 
Sommer, S. S., J. D. Cassady, J. L. Sobell and C. D. Bottema (1989). "A novel method for 
detecting point mutations or polymorphisms and its application to population screening for 
carriers of phenylketonuria." Mayo Clin Proc 64(11): 1361-1372. 
Sommer, S. S., A. R. Groszbach and C. D. Bottema (1992). "PCR amplification of specific 
alleles (PASA) is a general method for rapidly detecting known single-base changes." 
Biotechniques 12(1): 82-87. 
	  62	  
Spiess, A. N., N. Mueller and R. Ivell (2004). "Trehalose is a potent PCR enhancer: Lowering 
of DNA melting temperature and thermal stabilization of Taq polymerase by the 
disaccharide trehalose." Clinical Chemistry 50(7): 1256-1259. 
Stenman, J. and A. Orpana (2001). "Accuracy in amplification." Nat Biotechnol 19(11): 1011-
1012. 
Stenman, J., A. Paju, O. Rissanen, T. Tenkanen, C. Haglund, J. Räsänen, J. Salo, U. H. 
Stenman and A. Orpana (2006). "Targeted gene-expression analysis by genome-
controlled reverse transcription-PCR." Clin Chem 52(11): 1988-1996. 
Sternberg, D., C. Danan, A. Lombes, P. Laforet, E. Girodon, M. Goossens and S. Amselem 
(1998). "Exhaustive scanning approach to screen all the mitochondrial tRNA genes for 
mutations and its application to the investigation of 35 independent patients with 
mitochondrial disorders." Hum Mol Genet 7(1): 33-42. 
Strerath, M., J. Gaster, D. Summerer and A. Marx (2004). "Increased Single-Nucleotide 
Discrimination of PCR by Primer Probes Bearing Hydrophobic 4′C Modifications." 
ChemBioChem 5(3): 333-339. 
Sugimoto, N., M. Nakano and S. Nakano (2000). "Thermodynamics-structure relationship of 
single mismatches in RNA/DNA duplexes." Biochemistry 39(37): 11270-11281. 
Sun, Y., G. Hegamyer and N. H. Colburn (1993). "PCR-direct sequencing of a GC-rich region 
by inclusion of 10% DMSO: application to mouse c-jun." Biotechniques 15(3): 372-&. 
Syvanen, A. C. (1999). "From gels to chips: "minisequencing" primer extension for analysis of 
point mutations and single nucleotide polymorphisms." Hum Mutat 13(1): 1-10. 
Syvänen, A. C., K. Aalto-Setälä, L. Harju, K. Kontula and H. Söderlund (1990). "A primer-
guided nucleotide incorporation assay in the genotyping of apolipoprotein E." Genomics 
8(4): 684-692. 
Tan, J. A., J. S. Tay, L. I. Lin, S. K. Kham, J. N. Chia, T. M. Chin, N. B. Aziz and H. B. Wong 
(1994). "The amplification refractory mutation system (ARMS): a rapid and direct prenatal 
diagnostic technique for beta-thalassaemia in Singapore." Prenat Diagn 14(11): 1077-
1082. 
Thelwell, N., S. Millington, A. Solinas, J. Booth and T. Brown (2000). "Mode of action and 
application of Scorpion primers to mutation detection." Nucleic Acids Res 28(19): 3752-
3761. 
Thierry, A. R., F. Mouliere, S. El Messaoudi, C. Mollevi, E. Lopez-Crapez, F. Rolet, B. Gillet, 
C. Gongora, P. Dechelotte, B. Robert, M. Del Rio, P. J. Lamy, F. Bibeau, M. Nouaille, V. 
Loriot, A. S. Jarrousse, F. Molina, M. Mathonnet, D. Pezet and M. Ychou (2014). "Clinical 
validation of the detection of KRAS and BRAF mutations from circulating tumor DNA." Nat 
Med 20(4): 430-435. 
Toni, T. A., B. G. Brenner, E. L. Asahchop, M. Ntemgwa, D. Moisi and M. A. Wainberg 
(2010). "Development of an allele-specific PCR for detection of the K65R resistance 
mutation in patients infected with subtype C human immunodeficiency virus type 1." 
Antimicrob Agents Chemother 54(2): 907-911. 
Tsilfidis, C., A. E. MacKenzie, G. Mettler, J. Barcelo and R. G. Korneluk (1992). "Correlation 
between CTG trinucleotide repeat length and frequency of severe congenital myotonic 
dystrophy." Nat Genet 1(3): 192-195. 
Ugozzoli, L. A., D. Latorra, R. Puckett, K. Arar and K. Hamby (2004). "Real-time genotyping 
with oligonucleotide probes containing locked nucleic acids." Anal Biochem 324(1): 143-
152. 
Usdin, K. and K. J. Woodford (1995). "CGG repeats associated with DNA instability and 
chromosome fragility form structures that block DNA synthesis in vitro." Nucleic Acids Res 
23(20): 4202-4209. 
Van Cutsem, E., B. Nordlinger, R. Adam, C. H. Kohne, C. Pozzo, G. Poston, M. Ychou and P. 
Rougier (2006). "Towards a pan-European consensus on the treatment of patients with 
colorectal liver metastases." Eur J Cancer 42(14): 2212-2221. 
Van den Eynde, M. and A. Hendlisz (2009). "Treatment of colorectal liver metastases: a 
review." Rev Recent Clin Trials 4(1): 56-62. 
Varadaraj, K. and D. M. Skinner (1994). "Denaturants or Cosolvents Improve the Specificity of 
Pcr Amplification of a G+C-Rich DNA Using Genetically-Engineered DNA-Polymerases." 
Gene 140(1): 1-5. 
Verkerk, A. J., M. Pieretti, J. S. Sutcliffe, Y. H. Fu, D. P. Kuhl, A. Pizzuti, O. Reiner, S. 
Richards, M. F. Victoria, F. P. Zhang and et al. (1991). "Identification of a gene (FMR-1) 
	   63	  
containing a CGG repeat coincident with a breakpoint cluster region exhibiting length 
variation in fragile X syndrome." Cell 65(5): 905-914. 
Voss, K. O., K. P. Roos, R. L. Nonay and N. J. Dovichi (1998). "Combating PCR bias in 
bisulfite-based cytosine methylation analysis. Betaine-modified cytosine deamination 
PCR." Analytical Chemistry 70(18): 3818-3823. 
Wallace, R. B., M. J. Johnson, T. Hirose, T. Miyake, E. H. Kawashima and K. Itakura (1981). 
"The use of synthetic oligonucleotides as hybridization probes. II. Hybridization of 
oligonucleotides of mixed sequence to rabbit beta-globin DNA." Nucleic Acids Res 9(4): 
879-894. 
Walther, A., E. Johnstone, C. Swanton, R. Midgley, I. Tomlinson and D. Kerr (2009). "Genetic 
prognostic and predictive markers in colorectal cancer." Nat Rev Cancer 9(7): 489-499. 
Wang, H., J. Jiang, B. Mostert, A. Sieuwerts, J. W. Martens, S. Sleijfer, J. A. Foekens and Y. 
Wang (2013). "Allele-specific, non-extendable primer blocker PCR (AS-NEPB-PCR) for 
DNA mutation detection in cancer." J Mol Diagn 15(1): 62-69. 
Warnecke, P. M., C. Stirzaker, J. R. Melki, D. S. Millar, C. L. Paul and S. J. Clark (1997). 
"Detection and measurement of PCR bias in quantitative methylation analysis of 
bisulphite-treated DNA." Nucleic Acids Research 25(21): 4422-4426. 
Wei, M., J. Deng, K. Feng, B. Yu and Y. Chen (2010). "Universal method facilitating the 
amplification of extremely GC-rich DNA fragments from genomic DNA." Anal Chem 
82(14): 6303-6307. 
Whitcombe, D., J. Theaker, S. P. Guy, T. Brown and S. Little (1999). "Detection of PCR 
products using self-probing amplicons and fluorescence." Nat Biotechnol 17(8): 804-807. 
Wu, D. Y., L. Ugozzoli, B. K. Pal and R. B. Wallace (1989). "Allele-specific enzymatic 
amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia." Proc Natl 
Acad Sci U S A 86(8): 2757-2760. 
Yan, H., W. S. Yuan, V. E. Velculescu, B. Vogelstein and K. W. Kinzler (2002). "Allelic 
variation in human gene expression." Science 297(5584): 1143-1143. 
Zhang, H., X. Wang, Q. Ma, Z. Zhou and J. Fang (2011). "Rapid detection of low-abundance 
K-ras mutation in stools of colorectal cancer patients using chip-based temperature 
gradient capillary electrophoresis." Lab Invest 91(5): 788-798. 
Zhou, L., Y. Wang and C. T. Wittwer (2011). "Rare allele enrichment and detection by allele-
specific PCR, competitive probe blocking, and melting analysis." Biotechniques 50(5): 
311–318. 	  
	  64	  
ORIGINAL PUBLICATIONS 	  
